Triglycerides and Triglyceride-Rich Lipoproteins in the Causal Pathway of Cardiovascular Disease

Matthew Budoff

doi:10.1016/j.amjcard.2016.04.004

Review| Volume 118, ISSUE 1, P138-145, July 01, 2016

Triglycerides and Triglyceride-Rich Lipoproteins in the Causal Pathway of Cardiovascular Disease

Matthew Budoff, MD
Matthew Budoff
Correspondence
Corresponding author: Tel: (+1) 310-222-4107; fax: (+1) 310-787-0448.
Contact
Affiliations
Los Angeles Biomedical Research Institute, Harbor-University of California-Los Angeles, Torrance, California
Search for articles by this author

Open AccessPublished:April 19, 2016DOI:https://doi.org/10.1016/j.amjcard.2016.04.004

Epidemiologic and clinical studies suggest that elevated triglyceride levels are a biomarker of cardiovascular (CV) risk. Consistent with these findings, recent genetic evidence from mutational analyses, genome-wide association studies, and Mendelian randomization studies provide robust evidence that triglycerides and triglyceride-rich lipoproteins are in the causal pathway for atherosclerotic CV disease, indicating that they may play a pathogenic role, much like low-density lipoprotein cholesterol (LDL-C). Although statins are the cornerstone of dyslipidemia management, high triglyceride levels may persist in some patients despite statin therapy. Several triglyceride-lowering agents are available, including fibrates, niacin, and omega-3 fatty acids, of which prescription omega-3 fatty acids have the best tolerability and safety profile. In clinical studies, omega-3 fatty acids have been shown to reduce triglyceride levels, but products containing both eicosapentaenoic acid and docosahexaenoic acid may increase LDL-C levels. Icosapent ethyl, a high-purity eicosapentaenoic acid–only product, does not raise LDL-C levels and also reduces triglyceride, non–high-density lipoprotein cholesterol, and triglyceride-rich lipoprotein levels. In conclusion, omega-3 fatty acids are currently being evaluated in large CV outcome studies in statin-treated patients; these studies should help to elucidate the causative role of triglycerides in atherosclerotic CV disease.

Epidemiologic studies have demonstrated that elevated triglyceride levels are independently associated with increased cardiovascular (CV) risk.

¹

Boullart A.C.
de G.J.
Stalenhoef A.F.

Serum triglycerides and risk of cardiovascular disease.

Consistent with the epidemiologic data, clinical studies have shown that reaching target triglyceride levels correlates with reduced CV risk.

²

Miller M.
Stone N.J.
Ballantyne C.
Bittner V.
Criqui M.H.
Ginsberg H.N.
Goldberg A.C.
Howard W.J.
Jacobson M.S.
Kris-Etherton P.M.
Lennie T.A.
Levi M.
Mazzone T.
Pennathur S.

Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association.

Moreover, triglyceride lowering has been associated with reduced CV risk in certain patients with high baseline triglyceride levels.

²

Miller M.
Stone N.J.
Ballantyne C.
Bittner V.
Criqui M.H.
Ginsberg H.N.
Goldberg A.C.
Howard W.J.
Jacobson M.S.
Kris-Etherton P.M.
Lennie T.A.
Levi M.
Mazzone T.
Pennathur S.

Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association.

Together, these data infer that elevated triglyceride levels are a biomarker of CV risk. However, accumulating evidence reviewed herein suggests that triglycerides and triglyceride-rich lipoproteins (TRLs) are in the causal pathway of atherosclerotic CV disease (ASCVD), indicating that they play a pathogenic role in atherosclerosis rather than simply serving as a biomarker of disease risk. This study provides an overview of TRL metabolism, describes genetic evidence supporting the role of triglycerides and TRLs in the causal pathway of ASCVD, and discusses the relevance of these data for managing patients with dyslipidemia.

Overview of TRL Metabolism

Triglycerides are major components of TRLs, including very-low-density lipoprotein (VLDL) and chylomicrons, which are synthesized and secreted from the liver and intestinal enterocytes, respectively (Figure 1).

³

Khetarpal S.A.
Rader D.J.

Triglyceride-rich lipoproteins and coronary artery disease risk: new insights from human genetics.

Lipoprotein lipase (LPL) promotes hydrolysis of the core triglycerides in VLDL and chylomicrons, producing VLDL remnants and chylomicron remnants, both of which are enriched in cholesterol relative to triglycerides.

⁴

Wang H.
Eckel R.H.

Lipoprotein lipase: from gene to obesity.

Some of these particles may be taken up by the liver and cleared; those that remain in circulation are further modified by LPL and hepatic lipase, resulting in formation of cholesterol-enriched LDL particles.

³

Khetarpal S.A.
Rader D.J.

Triglyceride-rich lipoproteins and coronary artery disease risk: new insights from human genetics.

In the clinical setting, non–high-density lipoprotein cholesterol (non–HDL-C) reflects the cholesterol content found in all potentially atherogenic lipoproteins but principally in LDL and in the VLDL remnants and chylomicron remnants.

⁵

Jacobson T.A.
Ito M.K.
Maki K.C.
Orringer C.E.
Bays H.E.
Jones P.H.
McKenney J.M.
Grundy S.M.
Gill E.A.
Wild R.A.
Wilson D.P.
Brown W.V.

National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1-executive summary.

Therefore, to calculate remnant cholesterol (the cholesterol content found in the VLDL remnants and chylomicron remnants), the LDL cholesterol (LDL-C) level may be simply subtracted from the non–HDL-C level. As with LDL particles, VLDL remnants and chylomicron remnants can be taken up by macrophages in the arterial wall, where they may contribute to vascular inflammation and atherosclerotic plaque development and progression; however, unlike LDL particles, remnant particles do not require oxidative modification for this to occur.

³

Khetarpal S.A.
Rader D.J.

Triglyceride-rich lipoproteins and coronary artery disease risk: new insights from human genetics.

Figure thumbnail gr1 — Figure 1Schematic showing metabolism of TRLs. Factors that activate LPL lead to decreases in plasma triglyceride and TRL levels, whereas those that block LPL lead to increases in plasma triglyceride and TRL levels. ANGPTL = angiopoietin-like protein; HL = hepatic lipase.
Reproduced with permission from Khetarpal and Rader, 2015.
³
Khetarpal S.A.
Rader D.J.
Triglyceride-rich lipoproteins and coronary artery disease risk: new insights from human genetics.
*Arterioscler Thromb Vasc Biol.* 2015; 35: e3-e9
Crossref

PubMed

Scopus (46)

Google Scholar
View Large Image
Figure Viewer
Download Hi-res image
Download (PPT)

Several apolipoproteins (Apos) are components of VLDL and chylomicrons and are important in TRL metabolism. ApoC-II is a cofactor necessary for full activation of LPL,

⁴

Wang H.
Eckel R.H.

Lipoprotein lipase: from gene to obesity.

whereas ApoA-V appears to enhance LPL activity, possibly by facilitating interactions between LPL and TRLs. In contrast, ApoC-III inhibits LPL and may also contribute to hepatic VLDL assembly and secretion.

³

Khetarpal S.A.
Rader D.J.

Triglyceride-rich lipoproteins and coronary artery disease risk: new insights from human genetics.

The angiopoietin-like proteins ANGPTL3 and ANGPTL4 are secreted proteins that also inhibit LPL activity, potentially leading to increased triglyceride levels.

³

Khetarpal S.A.
Rader D.J.

Triglyceride-rich lipoproteins and coronary artery disease risk: new insights from human genetics.

^,

⁴

Wang H.
Eckel R.H.

Lipoprotein lipase: from gene to obesity.

Importantly, genetic alterations in these factors may have a substantial impact on TRL metabolism and triglyceride levels, and in turn, on atherosclerotic processes and CV outcomes. In addition, recent data from the Jackson Heart Study demonstrated that the ApoA-I/remnant ratio was strongly associated with coronary heart disease incidence.

⁶

May H.T.
Nelson J.R.
Lirette S.T.
Kulkarni K.R.
Anderson J.L.
Griswold M.E.
Horne B.D.
Correa A.
Muhlestein J.B.

The utility of the apolipoprotein A1 remnant ratio in predicting incidence coronary heart disease in a primary prevention cohort: the Jackson Heart Study.

Genetic Evidence for Triglycerides and TRLs in the Causal Pathway of ASCVD

Genetic variants in LPL and Apos involved in TRL metabolism have been identified and allow further evaluation of whether triglycerides and TRLs are involved in the causal pathway of ASCVD (Table 1, Table 2, Table 3).

⁷

Pollin T.I.
Damcott C.M.
Shen H.
Ott S.H.
Shelton J.
Horenstein R.B.
Post W.
McLenithan J.C.
Bielak L.F.
Peyser P.A.
Mitchell B.D.
Miller M.
O'Connell J.R.
Shuldiner A.R.

A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection.

^,

⁸

Jorgensen A.B.
Frikke-Schmidt R.
Nordestgaard B.G.
Tybjaerg-Hansen A.

Loss-of-function mutations in APOC3 and risk of ischemic vascular disease.

^,

⁹

Crosby J.
Peloso G.M.
Auer P.L.
Crosslin D.R.
Stitziel N.O.
Lange L.A.
Lu Y.
Tang Z.Z.
Zhang H.
Hindy G.
Masca N.
Stirrups K.
Kanoni S.
Do R.
Jun G.
Hu Y.
Kang H.M.
Xue C.
Goel A.
Farrall M.
Duga S.
Merlini P.A.
Asselta R.
Girelli D.
Olivieri O.
Martinelli N.
Yin W.
Reilly D.
Speliotes E.
Fox C.S.
Hveem K.
Holmen O.L.
Nikpay M.
Farlow D.N.
Assimes T.L.
Franceschini N.
Robinson J.
North K.E.
Martin L.W.
DePristo M.
Gupta N.
Escher S.A.
Jansson J.H.
Van Z.N.
Palmer C.N.
Wareham N.
Koch W.
Meitinger T.
Peters A.
Lieb W.
Erbel R.
Konig I.R.
Kruppa J.
Degenhardt F.
Gottesman O.
Bottinger E.P.
O'Donnell C.J.
Psaty B.M.
Ballantyne C.M.
Abecasis G.
Ordovas J.M.
Melander O.
Watkins H.
Orho-Melander M.
Ardissino D.
Loos R.J.
McPherson R.
Willer C.J.
Erdmann J.
Hall A.S.
Samani N.J.
Deloukas P.
Schunkert H.
Wilson J.G.
Kooperberg C.
Rich S.S.
Tracy R.P.
Lin D.Y.
Altshuler D.
Gabriel S.
Nickerson D.A.
Jarvik G.P.
Cupples L.A.
Reiner A.P.
Boerwinkle E.
Kathiresan S.

Loss-of-function mutations in APOC3, triglycerides, and coronary disease.

^,

¹⁰

Natarajan P.
Kohli P.
Baber U.
Nguyen K.D.
Sartori S.
Reilly D.F.
Mehran R.
Muntendam P.
Fuster V.
Rader D.J.
Kathiresan S.

Association of APOC3 loss-of-function mutations with plasma lipids and subclinical atherosclerosis.

^,

¹¹

Do R.
Stitziel N.O.
Won H.H.
Jorgensen A.B.
Duga S.
Angelica M.P.
Kiezun A.
Farrall M.
Goel A.
Zuk O.
Guella I.
Asselta R.
Lange L.A.
Peloso G.M.
Auer P.L.
Girelli D.
Martinelli N.
Farlow D.N.
DePristo M.A.
Roberts R.
Stewart A.F.
Saleheen D.
Danesh J.
Epstein S.E.
Sivapalaratnam S.
Hovingh G.K.
Kastelein J.J.
Samani N.J.
Schunkert H.
Erdmann J.
Shah S.H.
Kraus W.E.
Davies R.
Nikpay M.
Johansen C.T.
Wang J.
Hegele R.A.
Hechter E.
Marz W.
Kleber M.E.
Huang J.
Johnson A.D.
Li M.
Burke G.L.
Gross M.
Liu Y.
Assimes T.L.
Heiss G.
Lange E.M.
Folsom A.R.
Taylor H.A.
Olivieri O.
Hamsten A.
Clarke R.
Reilly D.F.
Yin W.
Rivas M.A.
Donnelly P.
Rossouw J.E.
Psaty B.M.
Herrington D.M.
Wilson J.G.
Rich S.S.
Bamshad M.J.
Tracy R.P.
Cupples L.A.
Rader D.J.
Reilly M.P.
Spertus J.A.
Cresci S.
Hartiala J.
Tang W.H.
Hazen S.L.
Allayee H.
Reiner A.P.
Carlson C.S.
Kooperberg C.
Jackson R.D.
Boerwinkle E.
Lander E.S.
Schwartz S.M.
Siscovick D.S.
McPherson R.
Tybjaerg-Hansen A.
Abecasis G.R.
Watkins H.
Nickerson D.A.
Ardissino D.
Sunyaev S.R.
O'Donnell C.J.
Altshuler D.
Gabriel S.
Kathiresan S.

Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction.

^,

¹²

Sarwar N.
Sandhu M.S.
Ricketts S.L.
Butterworth A.S.
Di A.E.
Boekholdt S.M.
Ouwehand W.
Watkins H.
Samani N.J.
Saleheen D.
Lawlor D.
Reilly M.P.
Hingorani A.D.
Talmud P.J.
Danesh J.

Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies.

^,

¹³

Dewey F.E.
Gusarova V.
O'Dushlaine C.
Gottesman O.
Trejos J.
Hunt C.
Van Hout C.V.
Habegger L.
Buckler D.
Lai K.M.V.
Leader J.B.
Murray M.F.
Ritchie M.D.
Kirchner H.L.
Ledbetter D.H.
Penn J.
Lopez A.
Borecki I.B.
Overton J.D.
Reid J.G.
Carey D.J.
Murphy A.J.
Yancopoulos G.D.
Baras A.
Gromada J.
Shuldiner A.R.

Inactivating variants in ANGPTL4 and risk of coronary artery disease.

^,

¹⁴

Stitziel N.
Stirrups K.
Masca N.
Erdmann J.
Kathiresan S.
Deloukas P.
Samani N.J.
Schunkert H.

Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease.

^,

¹⁵

Teslovich T.M.
Musunuru K.
Smith A.V.
Edmondson A.C.
Stylianou I.M.
Koseki M.
Pirruccello J.P.
Ripatti S.
Chasman D.I.
Willer C.J.
Johansen C.T.
Fouchier S.W.
Isaacs A.
Peloso G.M.
Barbalic M.
Ricketts S.L.
Bis J.C.
Aulchenko Y.S.
Thorleifsson G.
Feitosa M.F.
Chambers J.
Orho-Melander M.
Melander O.
Johnson T.
Li X.
Guo X.
Li M.
Shin C.Y.
Jin G.M.
Jin K.Y.
Lee J.Y.
Park T.
Kim K.
Sim X.
Twee-Hee O.R.
Croteau-Chonka D.C.
Lange L.A.
Smith J.D.
Song K.
Hua Z.J.
Yuan X.
Luan J.
Lamina C.
Ziegler A.
Zhang W.
Zee R.Y.
Wright A.F.
Witteman J.C.
Wilson J.F.
Willemsen G.
Wichmann H.E.
Whitfield J.B.
Waterworth D.M.
Wareham N.J.
Waeber G.
Vollenweider P.
Voight B.F.
Vitart V.
Uitterlinden A.G.
Uda M.
Tuomilehto J.
Thompson J.R.
Tanaka T.
Surakka I.
Stringham H.M.
Spector T.D.
Soranzo N.
Smit J.H.
Sinisalo J.
Silander K.
Sijbrands E.J.
Scuteri A.
Scott J.
Schlessinger D.
Sanna S.
Salomaa V.
Saharinen J.
Sabatti C.
Ruokonen A.
Rudan I.
Rose L.M.
Roberts R.
Rieder M.
Psaty B.M.
Pramstaller P.P.
Pichler I.
Perola M.
Penninx B.W.
Pedersen N.L.
Pattaro C.
Parker A.N.
Pare G.
Oostra B.A.
O'Donnell C.J.
Nieminen M.S.
Nickerson D.A.
Montgomery G.W.
Meitinger T.
McPherson R.
McCarthy M.I.
McArdle W.
Masson D.
Martin N.G.
Marroni F.
Mangino M.
Magnusson P.K.
Lucas G.
Luben R.
Loos R.J.
Lokki M.L.
Lettre G.
Langenberg C.
Launer L.J.
Lakatta E.G.
Laaksonen R.
Kyvik K.O.
Kronenberg F.
Konig I.R.
Khaw K.T.
Kaprio J.
Kaplan L.M.
Johansson A.
Jarvelin M.R.
Janssens A.C.
Ingelsson E.
Igl W.
Kees H.G.
Hottenga J.J.
Hofman A.
Hicks A.A.
Hengstenberg C.
Heid I.M.
Hayward C.
Havulinna A.S.
Hastie N.D.
Harris T.B.
Haritunians T.
Hall A.S.
Gyllensten U.
Guiducci C.
Groop L.C.
Gonzalez E.
Gieger C.
Freimer N.B.
Ferrucci L.
Erdmann J.
Elliott P.
Ejebe K.G.
Doring A.
Dominiczak A.F.
Demissie S.
Deloukas P.
de Geus E.J.
de Faire U.
Crawford G.
Collins F.S.
Chen Y.D.
Caulfield M.J.
Campbell H.
Burtt N.P.
Bonnycastle L.L.
Boomsma D.I.
Boekholdt S.M.
Bergman R.N.
Barroso I.
Bandinelli S.
Ballantyne C.M.
Assimes T.L.
Quertermous T.
Altshuler D.
Seielstad M.
Wong T.Y.
Tai E.S.
Feranil A.B.
Kuzawa C.W.
Adair L.S.
Taylor Jr., H.A.
Borecki I.B.
Gabriel S.B.
Wilson J.G.
Holm H.
Thorsteinsdottir U.
Gudnason V.
Krauss R.M.
Mohlke K.L.
Ordovas J.M.
Munroe P.B.
Kooner J.S.
Tall A.R.
Hegele R.A.
Kastelein J.J.
Schadt E.E.
Rotter J.I.
Boerwinkle E.
Strachan D.P.
Mooser V.
Stefansson K.
Reilly M.P.
Samani N.J.
Schunkert H.
Cupples L.A.
Sandhu M.S.
Ridker P.M.
Rader D.J.
van Duijn C.M.
Peltonen L.
Abecasis G.R.
Boehnke M.
Kathiresan S.

Biological, clinical and population relevance of 95 loci for blood lipids.

^,

¹⁶

Schunkert H.
Konig I.R.
Kathiresan S.
Reilly M.P.
Assimes T.L.
Holm H.
Preuss M.
Stewart A.F.
Barbalic M.
Gieger C.
Absher D.
Aherrahrou Z.
Allayee H.
Altshuler D.
Anand S.S.
Andersen K.
Anderson J.L.
Ardissino D.
Ball S.G.
Balmforth A.J.
Barnes T.A.
Becker D.M.
Becker L.C.
Berger K.
Bis J.C.
Boekholdt S.M.
Boerwinkle E.
Braund P.S.
Brown M.J.
Burnett M.S.
Buysschaert I.
Carlquist J.F.
Chen L.
Cichon S.
Codd V.
Davies R.W.
Dedoussis G.
Dehghan A.
Demissie S.
Devaney J.M.
Diemert P.
Do R.
Doering A.
Eifert S.
Mokhtari N.E.
Ellis S.G.
Elosua R.
Engert J.C.
Epstein S.E.
de Faire U.
Fischer M.
Folsom A.R.
Freyer J.
Gigante B.
Girelli D.
Gretarsdottir S.
Gudnason V.
Gulcher J.R.
Halperin E.
Hammond N.
Hazen S.L.
Hofman A.
Horne B.D.
Illig T.
Iribarren C.
Jones G.T.
Jukema J.W.
Kaiser M.A.
Kaplan L.M.
Kastelein J.J.
Khaw K.T.
Knowles J.W.
Kolovou G.
Kong A.
Laaksonen R.
Lambrechts D.
Leander K.
Lettre G.
Li M.
Lieb W.
Loley C.
Lotery A.J.
Mannucci P.M.
Maouche S.
Martinelli N.
McKeown P.P.
Meisinger C.
Meitinger T.
Melander O.
Merlini P.A.
Mooser V.
Morgan T.
Muhleisen T.W.
Muhlestein J.B.
Munzel T.
Musunuru K.
Nahrstaedt J.
Nelson C.P.
Nothen M.M.
Olivieri O.
Patel R.S.
Patterson C.C.
Peters A.
Peyvandi F.
Qu L.
Quyyumi A.A.
Rader D.J.
Rallidis L.S.
Rice C.
Rosendaal F.R.
Rubin D.
Salomaa V.
Sampietro M.L.
Sandhu M.S.
Schadt E.
Schafer A.
Schillert A.
Schreiber S.
Schrezenmeir J.
Schwartz S.M.
Siscovick D.S.
Sivananthan M.
Sivapalaratnam S.
Smith A.
Smith T.B.
Snoep J.D.
Soranzo N.
Spertus J.A.
Stark K.
Stirrups K.
Stoll M.
Tang W.H.
Tennstedt S.
Thorgeirsson G.
Thorleifsson G.
Tomaszewski M.
Uitterlinden A.G.
van Rij A.M.
Voight B.F.
Wareham N.J.
Wells G.A.
Wichmann H.E.
Wild P.S.
Willenborg C.
Witteman J.C.
Wright B.J.
Ye S.
Zeller T.
Ziegler A.
Cambien F.
Goodall A.H.
Cupples L.A.
Quertermous T.
Marz W.
Hengstenberg C.
Blankenberg S.
Ouwehand W.H.
Hall A.S.
Deloukas P.
Thompson J.R.
Stefansson K.
Roberts R.
Thorsteinsdottir U.
O'Donnell C.J.
McPherson R.
Erdmann J.
Samani N.J.

Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease.

^,

¹⁷

Willer C.J.
Schmidt E.M.
Sengupta S.
Peloso G.M.
Gustafsson S.
Kanoni S.
Ganna A.
Chen J.
Buchkovich M.L.
Mora S.
Beckmann J.S.
Bragg-Gresham J.L.
Chang H.Y.
Demirkan A.
Den Hertog H.M.
Do R.
Donnelly L.A.
Ehret G.B.
Esko T.
Feitosa M.F.
Ferreira T.
Fischer K.
Fontanillas P.
Fraser R.M.
Freitag D.F.
Gurdasani D.
Heikkila K.
Hypponen E.
Isaacs A.
Jackson A.U.
Johansson A.
Johnson T.
Kaakinen M.
Kettunen J.
Kleber M.E.
Li X.
Luan J.
Lyytikainen L.P.
Magnusson P.K.
Mangino M.
Mihailov E.
Montasser M.E.
Muller-Nurasyid M.
Nolte I.M.
O'Connell J.R.
Palmer C.D.
Perola M.
Petersen A.K.
Sanna S.
Saxena R.
Service S.K.
Shah S.
Shungin D.
Sidore C.
Song C.
Strawbridge R.J.
Surakka I.
Tanaka T.
Teslovich T.M.
Thorleifsson G.
Van den Herik E.G.
Voight B.F.
Volcik K.A.
Waite L.L.
Wong A.
Wu Y.
Zhang W.
Absher D.
Asiki G.
Barroso I.
Been L.F.
Bolton J.L.
Bonnycastle L.L.
Brambilla P.
Burnett M.S.
Cesana G.
Dimitriou M.
Doney A.S.
Doring A.
Elliott P.
Epstein S.E.
Eyjolfsson G.I.
Gigante B.
Goodarzi M.O.
Grallert H.
Gravito M.L.
Groves C.J.
Hallmans G.
Hartikainen A.L.
Hayward C.
Hernandez D.
Hicks A.A.
Holm H.
Hung Y.J.
Illig T.
Jones M.R.
Kaleebu P.
Kastelein J.J.
Khaw K.T.
Kim E.
Klopp N.
Komulainen P.
Kumari M.
Langenberg C.
Lehtimaki T.
Lin S.Y.
Lindstrom J.
Loos R.J.
Mach F.
McArdle W.L.
Meisinger C.
Mitchell B.D.
Muller G.
Nagaraja R.
Narisu N.
Nieminen T.V.
Nsubuga R.N.
Olafsson I.
Ong K.K.
Palotie A.
Papamarkou T.
Pomilla C.
Pouta A.
Rader D.J.
Reilly M.P.
Ridker P.M.
Rivadeneira F.
Rudan I.
Ruokonen A.
Samani N.
Scharnagl H.
Seeley J.
Silander K.
Stancakova A.
Stirrups K.
Swift A.J.
Tiret L.
Uitterlinden A.G.
van Pelt L.J.
Vedantam S.
Wainwright N.
Wijmenga C.
Wild S.H.
Willemsen G.
Wilsgaard T.
Wilson J.F.
Young E.H.
Zhao J.H.
Adair L.S.
Arveiler D.
Assimes T.L.
Bandinelli S.
Bennett F.
Bochud M.
Boehm B.O.
Boomsma D.I.
Borecki I.B.
Bornstein S.R.
Bovet P.
Burnier M.
Campbell H.
Chakravarti A.
Chambers J.C.
Chen Y.D.
Collins F.S.
Cooper R.S.
Danesh J.
Dedoussis G.
de Faire U.
Feranil A.B.
Ferrieres J.
Ferrucci L.
Freimer N.B.
Gieger C.
Groop L.C.
Gudnason V.
Gyllensten U.
Hamsten A.
Harris T.B.
Hingorani A.
Hirschhorn J.N.
Hofman A.
Hovingh G.K.
Hsiung C.A.
Humphries S.E.
Hunt S.C.
Hveem K.
Iribarren C.
Jarvelin M.R.
Jula A.
Kahonen M.
Kaprio J.
Kesaniemi A.
Kivimaki M.
Kooner J.S.
Koudstaal P.J.
Krauss R.M.
Kuh D.
Kuusisto J.
Kyvik K.O.
Laakso M.
Lakka T.A.
Lind L.
Lindgren C.M.
Martin N.G.
Marz W.
McCarthy M.I.
McKenzie C.A.
Meneton P.
Metspalu A.
Moilanen L.
Morris A.D.
Munroe P.B.
Njolstad I.
Pedersen N.L.
Power C.
Pramstaller P.P.
Price J.F.
Psaty B.M.
Quertermous T.
Rauramaa R.
Saleheen D.
Salomaa V.
Sanghera D.K.
Saramies J.
Schwarz P.E.
Sheu W.H.
Shuldiner A.R.
Siegbahn A.
Spector T.D.
Stefansson K.
Strachan D.P.
Tayo B.O.
Tremoli E.
Tuomilehto J.
Uusitupa M.
van Duijn C.M.
Vollenweider P.
Wallentin L.
Wareham N.J.
Whitfield J.B.
Wolffenbuttel B.H.
Ordovas J.M.
Boerwinkle E.
Palmer C.N.
Thorsteinsdottir U.
Chasman D.I.
Rotter J.I.
Franks P.W.
Ripatti S.
Cupples L.A.
Sandhu M.S.
Rich S.S.
Boehnke M.
Deloukas P.

Discovery and refinement of loci associated with lipid levels.

^,

¹⁸

Do R.
Willer C.J.
Schmidt E.M.
Sengupta S.
Gao C.
Peloso G.M.
Gustafsson S.
Kanoni S.
Ganna A.
Chen J.
Buchkovich M.L.
Mora S.
Beckmann J.S.
Bragg-Gresham J.L.
Chang H.Y.
Demirkan A.
Den Hertog H.M.
Donnelly L.A.
Ehret G.B.
Esko T.
Feitosa M.F.
Ferreira T.
Fischer K.
Fontanillas P.
Fraser R.M.
Freitag D.F.
Gurdasani D.
Heikkila K.
Hypponen E.
Isaacs A.
Jackson A.U.
Johansson A.
Johnson T.
Kaakinen M.
Kettunen J.
Kleber M.E.
Li X.
Luan J.
Lyytikainen L.P.
Magnusson P.K.
Mangino M.
Mihailov E.
Montasser M.E.
Muller-Nurasyid M.
Nolte I.M.
O'Connell J.R.
Palmer C.D.
Perola M.
Petersen A.K.
Sanna S.
Saxena R.
Service S.K.
Shah S.
Shungin D.
Sidore C.
Song C.
Strawbridge R.J.
Surakka I.
Tanaka T.
Teslovich T.M.
Thorleifsson G.
Van den Herik E.G.
Voight B.F.
Volcik K.A.
Waite L.L.
Wong A.
Wu Y.
Zhang W.
Absher D.
Asiki G.
Barroso I.
Been L.F.
Bolton J.L.
Bonnycastle L.L.
Brambilla P.
Burnett M.S.
Cesana G.
Dimitriou M.
Doney A.S.
Doring A.
Elliott P.
Epstein S.E.
Eyjolfsson G.I.
Gigante B.
Goodarzi M.O.
Grallert H.
Gravito M.L.
Groves C.J.
Hallmans G.
Hartikainen A.L.
Hayward C.
Hernandez D.
Hicks A.A.
Holm H.
Hung Y.J.
Illig T.
Jones M.R.
Kaleebu P.
Kastelein J.J.
Khaw K.T.
Kim E.
Klopp N.
Komulainen P.
Kumari M.
Langenberg C.
Lehtimaki T.
Lin S.Y.
Lindstrom J.
Loos R.J.
Mach F.
McArdle W.L.
Meisinger C.
Mitchell B.D.
Muller G.
Nagaraja R.
Narisu N.
Nieminen T.V.
Nsubuga R.N.
Olafsson I.
Ong K.K.
Palotie A.
Papamarkou T.
Pomilla C.
Pouta A.
Rader D.J.
Reilly M.P.
Ridker P.M.
Rivadeneira F.
Rudan I.
Ruokonen A.
Samani N.
Scharnagl H.
Seeley J.
Silander K.
Stancakova A.
Stirrups K.
Swift A.J.
Tiret L.
Uitterlinden A.G.
van Pelt L.J.
Vedantam S.
Wainwright N.
Wijmenga C.
Wild S.H.
Willemsen G.
Wilsgaard T.
Wilson J.F.
Young E.H.
Zhao J.H.
Adair L.S.
Arveiler D.
Assimes T.L.
Bandinelli S.
Bennett F.
Bochud M.
Boehm B.O.
Boomsma D.I.
Borecki I.B.
Bornstein S.R.
Bovet P.
Burnier M.
Campbell H.
Chakravarti A.
Chambers J.C.
Chen Y.D.
Collins F.S.
Cooper R.S.
Danesh J.
Dedoussis G.
de Faire U.
Feranil A.B.
Ferrieres J.
Ferrucci L.
Freimer N.B.
Gieger C.
Groop L.C.
Gudnason V.
Gyllensten U.
Hamsten A.
Harris T.B.
Hingorani A.
Hirschhorn J.N.
Hofman A.
Hovingh G.K.
Hsiung C.A.
Humphries S.E.
Hunt S.C.
Hveem K.
Iribarren C.
Jarvelin M.R.
Jula A.
Kahonen M.
Kaprio J.
Kesaniemi A.
Kivimaki M.
Kooner J.S.
Koudstaal P.J.
Krauss R.M.
Kuh D.
Kuusisto J.
Kyvik K.O.
Laakso M.
Lakka T.A.
Lind L.
Lindgren C.M.
Martin N.G.
Marz W.
McCarthy M.I.
McKenzie C.A.
Meneton P.
Metspalu A.
Moilanen L.
Morris A.D.
Munroe P.B.
Njolstad I.
Pedersen N.L.
Power C.
Pramstaller P.P.
Price J.F.
Psaty B.M.
Quertermous T.
Rauramaa R.
Saleheen D.
Salomaa V.
Sanghera D.K.
Saramies J.
Schwarz P.E.
Sheu W.H.
Shuldiner A.R.
Siegbahn A.
Spector T.D.
Stefansson K.
Strachan D.P.
Tayo B.O.
Tremoli E.
Tuomilehto J.
Uusitupa M.
van Duijn C.M.
Vollenweider P.
Wallentin L.
Wareham N.J.
Whitfield J.B.
Wolffenbuttel B.H.
Altshuler D.
Ordovas J.M.
Boerwinkle E.
Palmer C.N.
Thorsteinsdottir U.
Chasman D.I.
Rotter J.I.
Franks P.W.
Ripatti S.
Cupples L.A.
Sandhu M.S.
Rich S.S.

Common variants associated with plasma triglycerides and risk for coronary artery disease.

^,

¹⁹

Jorgensen A.B.
Frikke-Schmidt R.
West A.S.
Grande P.
Nordestgaard B.G.
Tybjaerg-Hansen A.

Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction.

^,

²⁰

Varbo A.
Benn M.
Tybjaerg-Hansen A.
Jorgensen A.B.
Frikke-Schmidt R.
Nordestgaard B.G.

Remnant cholesterol as a causal risk factor for ischemic heart disease.

^,

²¹

Varbo A.
Benn M.
Tybjaerg-Hansen A.
Nordestgaard B.G.

Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation.

^,

²²

Thomsen M.
Varbo A.
Tybjaerg-Hansen A.
Nordestgaard B.G.

Low nonfasting triglycerides and reduced all-cause mortality: a Mendelian randomization study.

^,

²³

Holmes M.V.
Asselbergs F.W.
Palmer T.M.
Drenos F.
Lanktree M.B.
Nelson C.P.
Dale C.E.
Padmanabhan S.
Finan C.
Swerdlow D.I.
Tragante V.
van Iperen E.P.
Sivapalaratnam S.
Shah S.
Elbers C.C.
Shah T.
Engmann J.
Giambartolomei C.
White J.
Zabaneh D.
Sofat R.
McLachlan S.
Doevendans P.A.
Balmforth A.J.
Hall A.S.
North K.E.
Almoguera B.
Hoogeveen R.C.
Cushman M.
Fornage M.
Patel S.R.
Redline S.
Siscovick D.S.
Tsai M.Y.
Karczewski K.J.
Hofker M.H.
Verschuren W.M.
Bots M.L.
van der Schouw Y.T.
Melander O.
Dominiczak A.F.
Morris R.
Ben-Shlomo Y.
Price J.
Kumari M.
Baumert J.
Peters A.
Thorand B.
Koenig W.
Gaunt T.R.
Humphries S.E.
Clarke R.
Watkins H.
Farrall M.
Wilson J.G.
Rich S.S.
de Bakker P.I.
Lange L.A.
Davey S.G.
Reiner A.P.
Talmud P.J.
Kivimaki M.
Lawlor D.A.
Dudbridge F.
Samani N.J.
Keating B.J.
Hingorani A.D.
Casas J.P.

Mendelian randomization of blood lipids for coronary heart disease.

Genetic data may be considered particularly compelling for evaluating whether a lipid biomarker is causally related to disease. Evaluation as to whether specific individual genetic loci are causally related to disease can overcome limitations associated with establishing causal inferences based on observational epidemiologic studies (e.g., reverse causation arising from interrelations among LDL-C, HDL-C, and triglycerides). Moreover, genetic data are not limited by confounding design issues that may complicate clinical studies, such as the use of inappropriate study populations, insufficient magnitude of triglyceride lowering, and limited statistical power.

Table 1Genetic data supporting causative role of triglycerides in atherosclerotic cardiovascular disease: mutational analyses

Reference	N	Variable	Effect on TGs	Effect on Cardiovascular Outcome
Pollin 2008 ⁷ Pollin T.I. Damcott C.M. Shen H. Ott S.H. Shelton J. Horenstein R.B. Post W. McLenithan J.C. Bielak L.F. Peyser P.A. Mitchell B.D. Miller M. O'Connell J.R. Shuldiner A.R. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science. 2008; 322: 1702-1705 Crossref PubMed Scopus (503) Google Scholar	809	ApoC-III R19X null mutation	–46% (P=4 × 10^-13)	CAC: OR=0.35 (95% CI: 0.21–0.60; P=0.002)
Jorgensen 2014 ⁸ Jorgensen A.B. Frikke-Schmidt R. Nordestgaard B.G. Tybjaerg-Hansen A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014; 371: 32-41 Crossref PubMed Scopus (605) Google Scholar	75,725	ApoC-III null mutations	–44% (P<0.001)	IVD: HR=0.59 (95% CI: 0.41–0.86; P=0.007) IHD: HR=0.64 (95% CI: 0.41–0.99; P=0.04)
Crosby 2014 ⁹ Crosby J. Peloso G.M. Auer P.L. Crosslin D.R. Stitziel N.O. Lange L.A. Lu Y. Tang Z.Z. Zhang H. Hindy G. Masca N. Stirrups K. Kanoni S. Do R. Jun G. Hu Y. Kang H.M. Xue C. Goel A. Farrall M. Duga S. Merlini P.A. Asselta R. Girelli D. Olivieri O. Martinelli N. Yin W. Reilly D. Speliotes E. Fox C.S. Hveem K. Holmen O.L. Nikpay M. Farlow D.N. Assimes T.L. Franceschini N. Robinson J. North K.E. Martin L.W. DePristo M. Gupta N. Escher S.A. Jansson J.H. Van Z.N. Palmer C.N. Wareham N. Koch W. Meitinger T. Peters A. Lieb W. Erbel R. Konig I.R. Kruppa J. Degenhardt F. Gottesman O. Bottinger E.P. O'Donnell C.J. Psaty B.M. Ballantyne C.M. Abecasis G. Ordovas J.M. Melander O. Watkins H. Orho-Melander M. Ardissino D. Loos R.J. McPherson R. Willer C.J. Erdmann J. Hall A.S. Samani N.J. Deloukas P. Schunkert H. Wilson J.G. Kooperberg C. Rich S.S. Tracy R.P. Lin D.Y. Altshuler D. Gabriel S. Nickerson D.A. Jarvik G.P. Cupples L.A. Reiner A.P. Boerwinkle E. Kathiresan S. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014; 371: 22-31 Crossref PubMed Scopus (720) Google Scholar	3,734	ApoC-III null mutations	–39% (P=6 × 10^-9)	CHD: OR=0.60 (95% CI: 0.47–0.75; P=4 × 10^-6)
Natarajan 2015 ¹⁰ Natarajan P. Kohli P. Baber U. Nguyen K.D. Sartori S. Reilly D.F. Mehran R. Muntendam P. Fuster V. Rader D.J. Kathiresan S. Association of APOC3 loss-of-function mutations with plasma lipids and subclinical atherosclerosis. J Am Coll Cardiol. 2015; 66: 2053-2055 Crossref PubMed Scopus (36) Google Scholar	6,699	ApoC-III null mutations	–43.7% (P=1.83 × 10^-21)	CAC: –27.9 U (95% CI: –51.1 to –4.7; P=0.019)
Do 2015 ¹¹ Do R. Stitziel N.O. Won H.H. Jorgensen A.B. Duga S. Angelica M.P. Kiezun A. Farrall M. Goel A. Zuk O. Guella I. Asselta R. Lange L.A. Peloso G.M. Auer P.L. Girelli D. Martinelli N. Farlow D.N. DePristo M.A. Roberts R. Stewart A.F. Saleheen D. Danesh J. Epstein S.E. Sivapalaratnam S. Hovingh G.K. Kastelein J.J. Samani N.J. Schunkert H. Erdmann J. Shah S.H. Kraus W.E. Davies R. Nikpay M. Johansen C.T. Wang J. Hegele R.A. Hechter E. Marz W. Kleber M.E. Huang J. Johnson A.D. Li M. Burke G.L. Gross M. Liu Y. Assimes T.L. Heiss G. Lange E.M. Folsom A.R. Taylor H.A. Olivieri O. Hamsten A. Clarke R. Reilly D.F. Yin W. Rivas M.A. Donnelly P. Rossouw J.E. Psaty B.M. Herrington D.M. Wilson J.G. Rich S.S. Bamshad M.J. Tracy R.P. Cupples L.A. Rader D.J. Reilly M.P. Spertus J.A. Cresci S. Hartiala J. Tang W.H. Hazen S.L. Allayee H. Reiner A.P. Carlson C.S. Kooperberg C. Jackson R.D. Boerwinkle E. Lander E.S. Schwartz S.M. Siscovick D.S. McPherson R. Tybjaerg-Hansen A. Abecasis G.R. Watkins H. Nickerson D.A. Ardissino D. Sunyaev S.R. O'Donnell C.J. Altshuler D. Gabriel S. Kathiresan S. Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature. 2015; 518: 102-106 Crossref PubMed Scopus (463) Google Scholar	13,432	ApoA-V mutations	+61% (P=0.007)	MI/CAD: OR=2.2 (P=5 × 10^-7)
Sarwar 2010 ¹² Sarwar N. Sandhu M.S. Ricketts S.L. Butterworth A.S. Di A.E. Boekholdt S.M. Ouwehand W. Watkins H. Samani N.J. Saleheen D. Lawlor D. Reilly M.P. Hingorani A.D. Talmud P.J. Danesh J. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet. 2010; 375: 1634-1639 Abstract Full Text Full Text PDF PubMed Scopus (540) Google Scholar	302,430	ApoA-V variant	+16% (P=4.4 × 10^-24)	CHD: HR=1.10 (95% CI: 1.08–1.12; P=2.6 × 10^-7)
Dewey 2016 ¹³ Dewey F.E. Gusarova V. O'Dushlaine C. Gottesman O. Trejos J. Hunt C. Van Hout C.V. Habegger L. Buckler D. Lai K.M.V. Leader J.B. Murray M.F. Ritchie M.D. Kirchner H.L. Ledbetter D.H. Penn J. Lopez A. Borecki I.B. Overton J.D. Reid J.G. Carey D.J. Murphy A.J. Yancopoulos G.D. Baras A. Gromada J. Shuldiner A.R. Inactivating variants in ANGPTL4 and risk of coronary artery disease. N Engl J Med. 2016; 374: 1123-1133 Crossref PubMed Scopus (297) Google Scholar	42,930	ANGPTL4 variants	–13% (P=2x10^-23)	CAD: OR=0.81 (95% CI: 0.70–0.92; P=0.002)
Stitziel 2016 ¹⁴ Stitziel N. Stirrups K. Masca N. Erdmann J. Kathiresan S. Deloukas P. Samani N.J. Schunkert H. Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease. N Engl J Med. 2016; 374: 1134-1144 Crossref PubMed Scopus (320) Google Scholar	120,575	ANGPTL4 variants	–0.3 standard deviations per allele	CAD: OR=0.86 (P=4.0 × 10^-8) ^∗ 95% CI not reported.

ANGPTL4 = angiopoietin-like 4; Apo = apolipoprotein; CAC = coronary artery calcification; CAD = coronary artery disease; CHD = coronary heart disease; CI = confidence interval; HR = hazard ratio; IHD = ischemic heart disease; IVD = ischemic vascular disease; MI = myocardial infarction; OR = odds ratio; TGs = triglycerides.

∗ 95% CI not reported.

Open table in a new tab

Table 2Genetic data supporting causative role of triglycerides in atherosclerotic cardiovascular disease: genome-wide association analyses

Reference	N	Study Type	Key Results
Teslovich, 2010 ¹⁵ Teslovich T.M. Musunuru K. Smith A.V. Edmondson A.C. Stylianou I.M. Koseki M. Pirruccello J.P. Ripatti S. Chasman D.I. Willer C.J. Johansen C.T. Fouchier S.W. Isaacs A. Peloso G.M. Barbalic M. Ricketts S.L. Bis J.C. Aulchenko Y.S. Thorleifsson G. Feitosa M.F. Chambers J. Orho-Melander M. Melander O. Johnson T. Li X. Guo X. Li M. Shin C.Y. Jin G.M. Jin K.Y. Lee J.Y. Park T. Kim K. Sim X. Twee-Hee O.R. Croteau-Chonka D.C. Lange L.A. Smith J.D. Song K. Hua Z.J. Yuan X. Luan J. Lamina C. Ziegler A. Zhang W. Zee R.Y. Wright A.F. Witteman J.C. Wilson J.F. Willemsen G. Wichmann H.E. Whitfield J.B. Waterworth D.M. Wareham N.J. Waeber G. Vollenweider P. Voight B.F. Vitart V. Uitterlinden A.G. Uda M. Tuomilehto J. Thompson J.R. Tanaka T. Surakka I. Stringham H.M. Spector T.D. Soranzo N. Smit J.H. Sinisalo J. Silander K. Sijbrands E.J. Scuteri A. Scott J. Schlessinger D. Sanna S. Salomaa V. Saharinen J. Sabatti C. Ruokonen A. Rudan I. Rose L.M. Roberts R. Rieder M. Psaty B.M. Pramstaller P.P. Pichler I. Perola M. Penninx B.W. Pedersen N.L. Pattaro C. Parker A.N. Pare G. Oostra B.A. O'Donnell C.J. Nieminen M.S. Nickerson D.A. Montgomery G.W. Meitinger T. McPherson R. McCarthy M.I. McArdle W. Masson D. Martin N.G. Marroni F. Mangino M. Magnusson P.K. Lucas G. Luben R. Loos R.J. Lokki M.L. Lettre G. Langenberg C. Launer L.J. Lakatta E.G. Laaksonen R. Kyvik K.O. Kronenberg F. Konig I.R. Khaw K.T. Kaprio J. Kaplan L.M. Johansson A. Jarvelin M.R. Janssens A.C. Ingelsson E. Igl W. Kees H.G. Hottenga J.J. Hofman A. Hicks A.A. Hengstenberg C. Heid I.M. Hayward C. Havulinna A.S. Hastie N.D. Harris T.B. Haritunians T. Hall A.S. Gyllensten U. Guiducci C. Groop L.C. Gonzalez E. Gieger C. Freimer N.B. Ferrucci L. Erdmann J. Elliott P. Ejebe K.G. Doring A. Dominiczak A.F. Demissie S. Deloukas P. de Geus E.J. de Faire U. Crawford G. Collins F.S. Chen Y.D. Caulfield M.J. Campbell H. Burtt N.P. Bonnycastle L.L. Boomsma D.I. Boekholdt S.M. Bergman R.N. Barroso I. Bandinelli S. Ballantyne C.M. Assimes T.L. Quertermous T. Altshuler D. Seielstad M. Wong T.Y. Tai E.S. Feranil A.B. Kuzawa C.W. Adair L.S. Taylor Jr., H.A. Borecki I.B. Gabriel S.B. Wilson J.G. Holm H. Thorsteinsdottir U. Gudnason V. Krauss R.M. Mohlke K.L. Ordovas J.M. Munroe P.B. Kooner J.S. Tall A.R. Hegele R.A. Kastelein J.J. Schadt E.E. Rotter J.I. Boerwinkle E. Strachan D.P. Mooser V. Stefansson K. Reilly M.P. Samani N.J. Schunkert H. Cupples L.A. Sandhu M.S. Ridker P.M. Rader D.J. van Duijn C.M. Peltonen L. Abecasis G.R. Boehnke M. Kathiresan S. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 2010; 466: 707-713 Crossref PubMed Scopus (2703) Google Scholar	96,598 ^∗ For triglycerides.	Meta-analysis of 46 lipid GWAS	Identified 95 loci, including regions encoding ANGPTL3 and ANGPTL4; 4 novel CAD-associated loci related to HDL-C or TGs but not LDL-C
Schunkert 2011 ¹⁶ Schunkert H. Konig I.R. Kathiresan S. Reilly M.P. Assimes T.L. Holm H. Preuss M. Stewart A.F. Barbalic M. Gieger C. Absher D. Aherrahrou Z. Allayee H. Altshuler D. Anand S.S. Andersen K. Anderson J.L. Ardissino D. Ball S.G. Balmforth A.J. Barnes T.A. Becker D.M. Becker L.C. Berger K. Bis J.C. Boekholdt S.M. Boerwinkle E. Braund P.S. Brown M.J. Burnett M.S. Buysschaert I. Carlquist J.F. Chen L. Cichon S. Codd V. Davies R.W. Dedoussis G. Dehghan A. Demissie S. Devaney J.M. Diemert P. Do R. Doering A. Eifert S. Mokhtari N.E. Ellis S.G. Elosua R. Engert J.C. Epstein S.E. de Faire U. Fischer M. Folsom A.R. Freyer J. Gigante B. Girelli D. Gretarsdottir S. Gudnason V. Gulcher J.R. Halperin E. Hammond N. Hazen S.L. Hofman A. Horne B.D. Illig T. Iribarren C. Jones G.T. Jukema J.W. Kaiser M.A. Kaplan L.M. Kastelein J.J. Khaw K.T. Knowles J.W. Kolovou G. Kong A. Laaksonen R. Lambrechts D. Leander K. Lettre G. Li M. Lieb W. Loley C. Lotery A.J. Mannucci P.M. Maouche S. Martinelli N. McKeown P.P. Meisinger C. Meitinger T. Melander O. Merlini P.A. Mooser V. Morgan T. Muhleisen T.W. Muhlestein J.B. Munzel T. Musunuru K. Nahrstaedt J. Nelson C.P. Nothen M.M. Olivieri O. Patel R.S. Patterson C.C. Peters A. Peyvandi F. Qu L. Quyyumi A.A. Rader D.J. Rallidis L.S. Rice C. Rosendaal F.R. Rubin D. Salomaa V. Sampietro M.L. Sandhu M.S. Schadt E. Schafer A. Schillert A. Schreiber S. Schrezenmeir J. Schwartz S.M. Siscovick D.S. Sivananthan M. Sivapalaratnam S. Smith A. Smith T.B. Snoep J.D. Soranzo N. Spertus J.A. Stark K. Stirrups K. Stoll M. Tang W.H. Tennstedt S. Thorgeirsson G. Thorleifsson G. Tomaszewski M. Uitterlinden A.G. van Rij A.M. Voight B.F. Wareham N.J. Wells G.A. Wichmann H.E. Wild P.S. Willenborg C. Witteman J.C. Wright B.J. Ye S. Zeller T. Ziegler A. Cambien F. Goodall A.H. Cupples L.A. Quertermous T. Marz W. Hengstenberg C. Blankenberg S. Ouwehand W.H. Hall A.S. Deloukas P. Thompson J.R. Stefansson K. Roberts R. Thorsteinsdottir U. O'Donnell C.J. McPherson R. Erdmann J. Samani N.J. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet. 2011; 43: 333-338 Crossref PubMed Scopus (1344) Google Scholar	147,733	Meta-analysis of 14 GWAS of CAD	Identified 13 novel loci associated with 6 to 17% increase in risk of CAD; included regions associated with increased TGs
Willer 2013 ¹⁷ Willer C.J. Schmidt E.M. Sengupta S. Peloso G.M. Gustafsson S. Kanoni S. Ganna A. Chen J. Buchkovich M.L. Mora S. Beckmann J.S. Bragg-Gresham J.L. Chang H.Y. Demirkan A. Den Hertog H.M. Do R. Donnelly L.A. Ehret G.B. Esko T. Feitosa M.F. Ferreira T. Fischer K. Fontanillas P. Fraser R.M. Freitag D.F. Gurdasani D. Heikkila K. Hypponen E. Isaacs A. Jackson A.U. Johansson A. Johnson T. Kaakinen M. Kettunen J. Kleber M.E. Li X. Luan J. Lyytikainen L.P. Magnusson P.K. Mangino M. Mihailov E. Montasser M.E. Muller-Nurasyid M. Nolte I.M. O'Connell J.R. Palmer C.D. Perola M. Petersen A.K. Sanna S. Saxena R. Service S.K. Shah S. Shungin D. Sidore C. Song C. Strawbridge R.J. Surakka I. Tanaka T. Teslovich T.M. Thorleifsson G. Van den Herik E.G. Voight B.F. Volcik K.A. Waite L.L. Wong A. Wu Y. Zhang W. Absher D. Asiki G. Barroso I. Been L.F. Bolton J.L. Bonnycastle L.L. Brambilla P. Burnett M.S. Cesana G. Dimitriou M. Doney A.S. Doring A. Elliott P. Epstein S.E. Eyjolfsson G.I. Gigante B. Goodarzi M.O. Grallert H. Gravito M.L. Groves C.J. Hallmans G. Hartikainen A.L. Hayward C. Hernandez D. Hicks A.A. Holm H. Hung Y.J. Illig T. Jones M.R. Kaleebu P. Kastelein J.J. Khaw K.T. Kim E. Klopp N. Komulainen P. Kumari M. Langenberg C. Lehtimaki T. Lin S.Y. Lindstrom J. Loos R.J. Mach F. McArdle W.L. Meisinger C. Mitchell B.D. Muller G. Nagaraja R. Narisu N. Nieminen T.V. Nsubuga R.N. Olafsson I. Ong K.K. Palotie A. Papamarkou T. Pomilla C. Pouta A. Rader D.J. Reilly M.P. Ridker P.M. Rivadeneira F. Rudan I. Ruokonen A. Samani N. Scharnagl H. Seeley J. Silander K. Stancakova A. Stirrups K. Swift A.J. Tiret L. Uitterlinden A.G. van Pelt L.J. Vedantam S. Wainwright N. Wijmenga C. Wild S.H. Willemsen G. Wilsgaard T. Wilson J.F. Young E.H. Zhao J.H. Adair L.S. Arveiler D. Assimes T.L. Bandinelli S. Bennett F. Bochud M. Boehm B.O. Boomsma D.I. Borecki I.B. Bornstein S.R. Bovet P. Burnier M. Campbell H. Chakravarti A. Chambers J.C. Chen Y.D. Collins F.S. Cooper R.S. Danesh J. Dedoussis G. de Faire U. Feranil A.B. Ferrieres J. Ferrucci L. Freimer N.B. Gieger C. Groop L.C. Gudnason V. Gyllensten U. Hamsten A. Harris T.B. Hingorani A. Hirschhorn J.N. Hofman A. Hovingh G.K. Hsiung C.A. Humphries S.E. Hunt S.C. Hveem K. Iribarren C. Jarvelin M.R. Jula A. Kahonen M. Kaprio J. Kesaniemi A. Kivimaki M. Kooner J.S. Koudstaal P.J. Krauss R.M. Kuh D. Kuusisto J. Kyvik K.O. Laakso M. Lakka T.A. Lind L. Lindgren C.M. Martin N.G. Marz W. McCarthy M.I. McKenzie C.A. Meneton P. Metspalu A. Moilanen L. Morris A.D. Munroe P.B. Njolstad I. Pedersen N.L. Power C. Pramstaller P.P. Price J.F. Psaty B.M. Quertermous T. Rauramaa R. Saleheen D. Salomaa V. Sanghera D.K. Saramies J. Schwarz P.E. Sheu W.H. Shuldiner A.R. Siegbahn A. Spector T.D. Stefansson K. Strachan D.P. Tayo B.O. Tremoli E. Tuomilehto J. Uusitupa M. van Duijn C.M. Vollenweider P. Wallentin L. Wareham N.J. Whitfield J.B. Wolffenbuttel B.H. Ordovas J.M. Boerwinkle E. Palmer C.N. Thorsteinsdottir U. Chasman D.I. Rotter J.I. Franks P.W. Ripatti S. Cupples L.A. Sandhu M.S. Rich S.S. Boehnke M. Deloukas P. Discovery and refinement of loci associated with lipid levels. Nat Genet. 2013; 45: 1274-1283 Crossref PubMed Scopus (1769) Google Scholar	188,578	Linear regression of 149 lipid SNPs	TG effect size correlated with CAD (Pearson r=0.46; P=0.02)
Do 2013 ¹⁸ Do R. Willer C.J. Schmidt E.M. Sengupta S. Gao C. Peloso G.M. Gustafsson S. Kanoni S. Ganna A. Chen J. Buchkovich M.L. Mora S. Beckmann J.S. Bragg-Gresham J.L. Chang H.Y. Demirkan A. Den Hertog H.M. Donnelly L.A. Ehret G.B. Esko T. Feitosa M.F. Ferreira T. Fischer K. Fontanillas P. Fraser R.M. Freitag D.F. Gurdasani D. Heikkila K. Hypponen E. Isaacs A. Jackson A.U. Johansson A. Johnson T. Kaakinen M. Kettunen J. Kleber M.E. Li X. Luan J. Lyytikainen L.P. Magnusson P.K. Mangino M. Mihailov E. Montasser M.E. Muller-Nurasyid M. Nolte I.M. O'Connell J.R. Palmer C.D. Perola M. Petersen A.K. Sanna S. Saxena R. Service S.K. Shah S. Shungin D. Sidore C. Song C. Strawbridge R.J. Surakka I. Tanaka T. Teslovich T.M. Thorleifsson G. Van den Herik E.G. Voight B.F. Volcik K.A. Waite L.L. Wong A. Wu Y. Zhang W. Absher D. Asiki G. Barroso I. Been L.F. Bolton J.L. Bonnycastle L.L. Brambilla P. Burnett M.S. Cesana G. Dimitriou M. Doney A.S. Doring A. Elliott P. Epstein S.E. Eyjolfsson G.I. Gigante B. Goodarzi M.O. Grallert H. Gravito M.L. Groves C.J. Hallmans G. Hartikainen A.L. Hayward C. Hernandez D. Hicks A.A. Holm H. Hung Y.J. Illig T. Jones M.R. Kaleebu P. Kastelein J.J. Khaw K.T. Kim E. Klopp N. Komulainen P. Kumari M. Langenberg C. Lehtimaki T. Lin S.Y. Lindstrom J. Loos R.J. Mach F. McArdle W.L. Meisinger C. Mitchell B.D. Muller G. Nagaraja R. Narisu N. Nieminen T.V. Nsubuga R.N. Olafsson I. Ong K.K. Palotie A. Papamarkou T. Pomilla C. Pouta A. Rader D.J. Reilly M.P. Ridker P.M. Rivadeneira F. Rudan I. Ruokonen A. Samani N. Scharnagl H. Seeley J. Silander K. Stancakova A. Stirrups K. Swift A.J. Tiret L. Uitterlinden A.G. van Pelt L.J. Vedantam S. Wainwright N. Wijmenga C. Wild S.H. Willemsen G. Wilsgaard T. Wilson J.F. Young E.H. Zhao J.H. Adair L.S. Arveiler D. Assimes T.L. Bandinelli S. Bennett F. Bochud M. Boehm B.O. Boomsma D.I. Borecki I.B. Bornstein S.R. Bovet P. Burnier M. Campbell H. Chakravarti A. Chambers J.C. Chen Y.D. Collins F.S. Cooper R.S. Danesh J. Dedoussis G. de Faire U. Feranil A.B. Ferrieres J. Ferrucci L. Freimer N.B. Gieger C. Groop L.C. Gudnason V. Gyllensten U. Hamsten A. Harris T.B. Hingorani A. Hirschhorn J.N. Hofman A. Hovingh G.K. Hsiung C.A. Humphries S.E. Hunt S.C. Hveem K. Iribarren C. Jarvelin M.R. Jula A. Kahonen M. Kaprio J. Kesaniemi A. Kivimaki M. Kooner J.S. Koudstaal P.J. Krauss R.M. Kuh D. Kuusisto J. Kyvik K.O. Laakso M. Lakka T.A. Lind L. Lindgren C.M. Martin N.G. Marz W. McCarthy M.I. McKenzie C.A. Meneton P. Metspalu A. Moilanen L. Morris A.D. Munroe P.B. Njolstad I. Pedersen N.L. Power C. Pramstaller P.P. Price J.F. Psaty B.M. Quertermous T. Rauramaa R. Saleheen D. Salomaa V. Sanghera D.K. Saramies J. Schwarz P.E. Sheu W.H. Shuldiner A.R. Siegbahn A. Spector T.D. Stefansson K. Strachan D.P. Tayo B.O. Tremoli E. Tuomilehto J. Uusitupa M. van Duijn C.M. Vollenweider P. Wallentin L. Wareham N.J. Whitfield J.B. Wolffenbuttel B.H. Altshuler D. Ordovas J.M. Boerwinkle E. Palmer C.N. Thorsteinsdottir U. Chasman D.I. Rotter J.I. Franks P.W. Ripatti S. Cupples L.A. Sandhu M.S. Rich S.S. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet. 2013; 45: 1345-1352 Crossref PubMed Scopus (574) Google Scholar	188,577	Multivariate analysis of 185 lipid SNPs	TG effect size correlated with CHD after adjusting for LDL-C and HDL-C effect sizes (P=1 x 10^-9)

Apo = apolipoprotein; CAD = coronary artery disease; CHD = coronary heart disease; GWAS = genome-wide association studies; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; SNPs = single nucleotide polymorphisms; TGs = triglycerides.

∗ For triglycerides.

Open table in a new tab

Table 3Genetic data supporting causative role of triglycerides in atherosclerotic cardiovascular disease: Mendelian randomization studies

Reference	N	Variable	Effect on TGs	Effect on Cardiovascular Outcome
Jorgensen 2013 ¹⁹ Jorgensen A.B. Frikke-Schmidt R. West A.S. Grande P. Nordestgaard B.G. Tybjaerg-Hansen A. Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur Heart J. 2013; 34: 1826-1833 Crossref PubMed Scopus (253) Google Scholar	60,113	10 combinations of 3 APOA5 variants	Stepwise increase up to 56%	MI: causal OR=1.94 (95% CI: 1.40–1.85); observational OR=1.57 (95% CI: 1.32–2.68) ^∗ For doubling of nonfasting triglyceride levels.
Varbo 2013 ²⁰ Varbo A. Benn M. Tybjaerg-Hansen A. Jorgensen A.B. Frikke-Schmidt R. Nordestgaard B.G. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013; 61: 427-436 Abstract Full Text Full Text PDF PubMed Scopus (572) Google Scholar	73,513	3 non-fasting cholesterol-increasing alleles	Correlated with remnant cholesterol (r²=0.96)	IHD: causal OR=2.8 (95% CI: 1.9–4.2); observational OR=1.4 (95% CI: 1.3–1.5) ^† For 1 mmol/L (39 mg/dl) increase in remnant cholesterol levels.
Varbo 2013 ²¹ Varbo A. Benn M. Tybjaerg-Hansen A. Nordestgaard B.G. Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation. 2013; 128: 1298-1309 Crossref PubMed Scopus (250) Google Scholar	60,608	6 non-fasting cholesterol-increasing alleles	Not measured	IHD: causal OR=3.3 (95% CI: 2.1–5.2); observational OR=1.3 (95% CI: 1.2–1.4) ^† For 1 mmol/L (39 mg/dl) increase in remnant cholesterol levels.
Thomsen 2014 ²² Thomsen M. Varbo A. Tybjaerg-Hansen A. Nordestgaard B.G. Low nonfasting triglycerides and reduced all-cause mortality: a Mendelian randomization study. Clin Chem. 2014; 60: 737-746 Crossref PubMed Scopus (114) Google Scholar	10,208	4 LPL genetic variants	Stepwise decrease up to 31% ^‡ With increasing number of LPL alleles.	All-cause mortality: HR=0.86 for 6 LPL alleles vs 0–3 LPL alleles (95% CI: 0.83–0.88)
Holmes 2015 ²³ Holmes M.V. Asselbergs F.W. Palmer T.M. Drenos F. Lanktree M.B. Nelson C.P. Dale C.E. Padmanabhan S. Finan C. Swerdlow D.I. Tragante V. van Iperen E.P. Sivapalaratnam S. Shah S. Elbers C.C. Shah T. Engmann J. Giambartolomei C. White J. Zabaneh D. Sofat R. McLachlan S. Doevendans P.A. Balmforth A.J. Hall A.S. North K.E. Almoguera B. Hoogeveen R.C. Cushman M. Fornage M. Patel S.R. Redline S. Siscovick D.S. Tsai M.Y. Karczewski K.J. Hofker M.H. Verschuren W.M. Bots M.L. van der Schouw Y.T. Melander O. Dominiczak A.F. Morris R. Ben-Shlomo Y. Price J. Kumari M. Baumert J. Peters A. Thorand B. Koenig W. Gaunt T.R. Humphries S.E. Clarke R. Watkins H. Farrall M. Wilson J.G. Rich S.S. de Bakker P.I. Lange L.A. Davey S.G. Reiner A.P. Talmud P.J. Kivimaki M. Lawlor D.A. Dudbridge F. Samani N.J. Keating B.J. Hingorani A.D. Casas J.P. Mendelian randomization of blood lipids for coronary heart disease. Eur Heart J. 2015; 36: 539-550 Crossref PubMed Scopus (400) Google Scholar	62,199 ^¶ Meta-analysis of 17 studies.	67 triglyceride-related SNPs	Mean increase of 28.5%	CHD ^§ Unrestricted allele scores were based on all 67 triglyceride-related SNPs; restricted allele scores were for 1-log increment in triglyceride level and included only 27 triglyceride-related SNPs that were not also associated with LDL-C or HDL-C. : OR (unrestricted)=1.62 (95% CI: 1.24– 2.11); OR (restricted)=1.61 (95% CI: 1.00–2.59)

Apo = apolipoprotein; CHD = coronary heart disease; CI = confidence interval; HDL-C = high-density lipoprotein cholesterol; IHD = ischemic heart disease; LDL-C = low-density lipoprotein cholesterol; LPL = lipoprotein lipase; MI = myocardial infarction; OR = odds ratio; SNPs = single nucleotide polymorphisms; TGs = triglycerides.

∗ For doubling of nonfasting triglyceride levels.

† For 1 mmol/L (39 mg/dl) increase in remnant cholesterol levels.

‡ With increasing number of LPL alleles.

§ Unrestricted allele scores were based on all 67 triglyceride-related SNPs; restricted allele scores were for 1-log increment in triglyceride level and included only 27 triglyceride-related SNPs that were not also associated with LDL-C or HDL-C.

¶ Meta-analysis of 17 studies.

Open table in a new tab

Mutational analyses/exome sequencing

Early studies found that mutations conferring reduced TRL metabolism are associated with atherosclerosis and CHD, whereas those enhancing TRL metabolism have the opposite clinical effect. Several substitution mutations have been identified at the N-terminal end of LPL that reduce its catalytic activity. In a meta-analysis, carriers of the Gly188Glu substitution mutation in LPL had reduced LPL activity, an average increase in triglyceride levels of 78%, and a nearly fivefold increased CHD risk compared with noncarriers.

²⁴

Wittrup H.H.
Tybjaerg-Hansen A.
Nordestgaard B.G.

Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis.

The effects of the Asp91Asn and Asn291Ser mutations on LPL activity and triglyceride levels were smaller, and they had only a borderline effect on CHD risk. Loss-of-function mutations in ApoC-II, the activating cofactor for LPL, have been reported to cause profound increases in serum triglyceride levels leading to chylomicronemia and pancreatitis.

²⁵

Breckenridge W.C.
Little J.A.
Steiner G.
Chow A.
Poapst M.

Hypertriglyceridemia associated with deficiency of apolipoprotein C-II.

^,

²⁶

Reina M.
Brunzell J.D.
Deeb S.S.

Molecular basis of familial chylomicronemia: mutations in the lipoprotein lipase and apolipoprotein C-II genes.

Similarly, mutations in the gene encoding ApoA-V have been associated with increased triglyceride levels as well as higher risk of myocardial infarction (MI)/coronary artery disease

¹¹

Do R.
Stitziel N.O.
Won H.H.
Jorgensen A.B.
Duga S.
Angelica M.P.
Kiezun A.
Farrall M.
Goel A.
Zuk O.
Guella I.
Asselta R.
Lange L.A.
Peloso G.M.
Auer P.L.
Girelli D.
Martinelli N.
Farlow D.N.
DePristo M.A.
Roberts R.
Stewart A.F.
Saleheen D.
Danesh J.
Epstein S.E.
Sivapalaratnam S.
Hovingh G.K.
Kastelein J.J.
Samani N.J.
Schunkert H.
Erdmann J.
Shah S.H.
Kraus W.E.
Davies R.
Nikpay M.
Johansen C.T.
Wang J.
Hegele R.A.
Hechter E.
Marz W.
Kleber M.E.
Huang J.
Johnson A.D.
Li M.
Burke G.L.
Gross M.
Liu Y.
Assimes T.L.
Heiss G.
Lange E.M.
Folsom A.R.
Taylor H.A.
Olivieri O.
Hamsten A.
Clarke R.
Reilly D.F.
Yin W.
Rivas M.A.
Donnelly P.
Rossouw J.E.
Psaty B.M.
Herrington D.M.
Wilson J.G.
Rich S.S.
Bamshad M.J.
Tracy R.P.
Cupples L.A.
Rader D.J.
Reilly M.P.
Spertus J.A.
Cresci S.
Hartiala J.
Tang W.H.
Hazen S.L.
Allayee H.
Reiner A.P.
Carlson C.S.
Kooperberg C.
Jackson R.D.
Boerwinkle E.
Lander E.S.
Schwartz S.M.
Siscovick D.S.
McPherson R.
Tybjaerg-Hansen A.
Abecasis G.R.
Watkins H.
Nickerson D.A.
Ardissino D.
Sunyaev S.R.
O'Donnell C.J.
Altshuler D.
Gabriel S.
Kathiresan S.

Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction.

and increased risk of CHD (Table 1).

¹²

Sarwar N.
Sandhu M.S.
Ricketts S.L.
Butterworth A.S.
Di A.E.
Boekholdt S.M.
Ouwehand W.
Watkins H.
Samani N.J.
Saleheen D.
Lawlor D.
Reilly M.P.
Hingorani A.D.
Talmud P.J.
Danesh J.

Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies.

Mutations in APOC3 have the opposite effect, consistent with the inhibitory effect of this Apo on LPL activity. In a cohort of Amish subjects, carriers of an R19X mutation in APOC3 had a 46% reduction in serum triglyceride levels compared with noncarriers, which was associated with a 65% reduction in risk of coronary artery calcification, a measure of subclinical atherosclerosis (p = 0.002).

⁷

Pollin T.I.
Damcott C.M.
Shen H.
Ott S.H.
Shelton J.
Horenstein R.B.
Post W.
McLenithan J.C.
Bielak L.F.
Peyser P.A.
Mitchell B.D.
Miller M.
O'Connell J.R.
Shuldiner A.R.

A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection.

Consistent with these findings, rare loss-of-function APOC3 mutations found through exome sequencing were associated with decreased triglyceride levels and CHD risk compared with noncarriers in 2 recent studies (Table 1).

⁸

Jorgensen A.B.
Frikke-Schmidt R.
Nordestgaard B.G.
Tybjaerg-Hansen A.

Loss-of-function mutations in APOC3 and risk of ischemic vascular disease.

^,

⁹

Crosby J.
Peloso G.M.
Auer P.L.
Crosslin D.R.
Stitziel N.O.
Lange L.A.
Lu Y.
Tang Z.Z.
Zhang H.
Hindy G.
Masca N.
Stirrups K.
Kanoni S.
Do R.
Jun G.
Hu Y.
Kang H.M.
Xue C.
Goel A.
Farrall M.
Duga S.
Merlini P.A.
Asselta R.
Girelli D.
Olivieri O.
Martinelli N.
Yin W.
Reilly D.
Speliotes E.
Fox C.S.
Hveem K.
Holmen O.L.
Nikpay M.
Farlow D.N.
Assimes T.L.
Franceschini N.
Robinson J.
North K.E.
Martin L.W.
DePristo M.
Gupta N.
Escher S.A.
Jansson J.H.
Van Z.N.
Palmer C.N.
Wareham N.
Koch W.
Meitinger T.
Peters A.
Lieb W.
Erbel R.
Konig I.R.
Kruppa J.
Degenhardt F.
Gottesman O.
Bottinger E.P.
O'Donnell C.J.
Psaty B.M.
Ballantyne C.M.
Abecasis G.
Ordovas J.M.
Melander O.
Watkins H.
Orho-Melander M.
Ardissino D.
Loos R.J.
McPherson R.
Willer C.J.
Erdmann J.
Hall A.S.
Samani N.J.
Deloukas P.
Schunkert H.
Wilson J.G.
Kooperberg C.
Rich S.S.
Tracy R.P.
Lin D.Y.
Altshuler D.
Gabriel S.
Nickerson D.A.
Jarvik G.P.
Cupples L.A.
Reiner A.P.
Boerwinkle E.
Kathiresan S.

Loss-of-function mutations in APOC3, triglycerides, and coronary disease.

Similarly, a recent analysis of APOC3 mutations in subjects of European, African, Asian, and Hispanic ancestries also found that carriers had reduced plasma triglycerides and decreased burden of coronary artery calcification (Table 1).

¹⁰

Natarajan P.
Kohli P.
Baber U.
Nguyen K.D.
Sartori S.
Reilly D.F.
Mehran R.
Muntendam P.
Fuster V.
Rader D.J.
Kathiresan S.

Association of APOC3 loss-of-function mutations with plasma lipids and subclinical atherosclerosis.

Most recently, ANGPTL4 mutations were shown to be associated with lower triglyceride levels and lower risk of coronary artery disease (Table 1).

¹³

Dewey F.E.
Gusarova V.
O'Dushlaine C.
Gottesman O.
Trejos J.
Hunt C.
Van Hout C.V.
Habegger L.
Buckler D.
Lai K.M.V.
Leader J.B.
Murray M.F.
Ritchie M.D.
Kirchner H.L.
Ledbetter D.H.
Penn J.
Lopez A.
Borecki I.B.
Overton J.D.
Reid J.G.
Carey D.J.
Murphy A.J.
Yancopoulos G.D.
Baras A.
Gromada J.
Shuldiner A.R.

Inactivating variants in ANGPTL4 and risk of coronary artery disease.

^,

¹⁴

Stitziel N.
Stirrups K.
Masca N.
Erdmann J.
Kathiresan S.
Deloukas P.
Samani N.J.
Schunkert H.

Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease.

Genome-wide association studies

Genome-wide association studies are designed to search large cohorts for common genetic variants, such as single nucleotide polymorphisms (SNPs) that occur more frequently in patients with a certain disease compared with those without the disease, to identify susceptibility genes that may contribute to that disease. Genome-wide association studies have been conducted to identify susceptibility loci for CHD as well as specific lipid traits that have been associated with CHD; these studies detected susceptibility loci in gene regions encoding ApoC-III, ApoA-V, ANGPTL3, and ANGPTL4 (Table 2).

¹⁵

Teslovich T.M.
Musunuru K.
Smith A.V.
Edmondson A.C.
Stylianou I.M.
Koseki M.
Pirruccello J.P.
Ripatti S.
Chasman D.I.
Willer C.J.
Johansen C.T.
Fouchier S.W.
Isaacs A.
Peloso G.M.
Barbalic M.
Ricketts S.L.
Bis J.C.
Aulchenko Y.S.
Thorleifsson G.
Feitosa M.F.
Chambers J.
Orho-Melander M.
Melander O.
Johnson T.
Li X.
Guo X.
Li M.
Shin C.Y.
Jin G.M.
Jin K.Y.
Lee J.Y.
Park T.
Kim K.
Sim X.
Twee-Hee O.R.
Croteau-Chonka D.C.
Lange L.A.
Smith J.D.
Song K.
Hua Z.J.
Yuan X.
Luan J.
Lamina C.
Ziegler A.
Zhang W.
Zee R.Y.
Wright A.F.
Witteman J.C.
Wilson J.F.
Willemsen G.
Wichmann H.E.
Whitfield J.B.
Waterworth D.M.
Wareham N.J.
Waeber G.
Vollenweider P.
Voight B.F.
Vitart V.
Uitterlinden A.G.
Uda M.
Tuomilehto J.
Thompson J.R.
Tanaka T.
Surakka I.
Stringham H.M.
Spector T.D.
Soranzo N.
Smit J.H.
Sinisalo J.
Silander K.
Sijbrands E.J.
Scuteri A.
Scott J.
Schlessinger D.
Sanna S.
Salomaa V.
Saharinen J.
Sabatti C.
Ruokonen A.
Rudan I.
Rose L.M.
Roberts R.
Rieder M.
Psaty B.M.
Pramstaller P.P.
Pichler I.
Perola M.
Penninx B.W.
Pedersen N.L.
Pattaro C.
Parker A.N.
Pare G.
Oostra B.A.
O'Donnell C.J.
Nieminen M.S.
Nickerson D.A.
Montgomery G.W.
Meitinger T.
McPherson R.
McCarthy M.I.
McArdle W.
Masson D.
Martin N.G.
Marroni F.
Mangino M.
Magnusson P.K.
Lucas G.
Luben R.
Loos R.J.
Lokki M.L.
Lettre G.
Langenberg C.
Launer L.J.
Lakatta E.G.
Laaksonen R.
Kyvik K.O.
Kronenberg F.
Konig I.R.
Khaw K.T.
Kaprio J.
Kaplan L.M.
Johansson A.
Jarvelin M.R.
Janssens A.C.
Ingelsson E.
Igl W.
Kees H.G.
Hottenga J.J.
Hofman A.
Hicks A.A.
Hengstenberg C.
Heid I.M.
Hayward C.
Havulinna A.S.
Hastie N.D.
Harris T.B.
Haritunians T.
Hall A.S.
Gyllensten U.
Guiducci C.
Groop L.C.
Gonzalez E.
Gieger C.
Freimer N.B.
Ferrucci L.
Erdmann J.
Elliott P.
Ejebe K.G.
Doring A.
Dominiczak A.F.
Demissie S.
Deloukas P.
de Geus E.J.
de Faire U.
Crawford G.
Collins F.S.
Chen Y.D.
Caulfield M.J.
Campbell H.
Burtt N.P.
Bonnycastle L.L.
Boomsma D.I.
Boekholdt S.M.
Bergman R.N.
Barroso I.
Bandinelli S.
Ballantyne C.M.
Assimes T.L.
Quertermous T.
Altshuler D.
Seielstad M.
Wong T.Y.
Tai E.S.
Feranil A.B.
Kuzawa C.W.
Adair L.S.
Taylor Jr., H.A.
Borecki I.B.
Gabriel S.B.
Wilson J.G.
Holm H.
Thorsteinsdottir U.
Gudnason V.
Krauss R.M.
Mohlke K.L.
Ordovas J.M.
Munroe P.B.
Kooner J.S.
Tall A.R.
Hegele R.A.
Kastelein J.J.
Schadt E.E.
Rotter J.I.
Boerwinkle E.
Strachan D.P.
Mooser V.
Stefansson K.
Reilly M.P.
Samani N.J.
Schunkert H.
Cupples L.A.
Sandhu M.S.
Ridker P.M.
Rader D.J.
van Duijn C.M.
Peltonen L.
Abecasis G.R.
Boehnke M.
Kathiresan S.

Biological, clinical and population relevance of 95 loci for blood lipids.

^,

¹⁶

Schunkert H.
Konig I.R.
Kathiresan S.
Reilly M.P.
Assimes T.L.
Holm H.
Preuss M.
Stewart A.F.
Barbalic M.
Gieger C.
Absher D.
Aherrahrou Z.
Allayee H.
Altshuler D.
Anand S.S.
Andersen K.
Anderson J.L.
Ardissino D.
Ball S.G.
Balmforth A.J.
Barnes T.A.
Becker D.M.
Becker L.C.
Berger K.
Bis J.C.
Boekholdt S.M.
Boerwinkle E.
Braund P.S.
Brown M.J.
Burnett M.S.
Buysschaert I.
Carlquist J.F.
Chen L.
Cichon S.
Codd V.
Davies R.W.
Dedoussis G.
Dehghan A.
Demissie S.
Devaney J.M.
Diemert P.
Do R.
Doering A.
Eifert S.
Mokhtari N.E.
Ellis S.G.
Elosua R.
Engert J.C.
Epstein S.E.
de Faire U.
Fischer M.
Folsom A.R.
Freyer J.
Gigante B.
Girelli D.
Gretarsdottir S.
Gudnason V.
Gulcher J.R.
Halperin E.
Hammond N.
Hazen S.L.
Hofman A.
Horne B.D.
Illig T.
Iribarren C.
Jones G.T.
Jukema J.W.
Kaiser M.A.
Kaplan L.M.
Kastelein J.J.
Khaw K.T.
Knowles J.W.
Kolovou G.
Kong A.
Laaksonen R.
Lambrechts D.
Leander K.
Lettre G.
Li M.
Lieb W.
Loley C.
Lotery A.J.
Mannucci P.M.
Maouche S.
Martinelli N.
McKeown P.P.
Meisinger C.
Meitinger T.
Melander O.
Merlini P.A.
Mooser V.
Morgan T.
Muhleisen T.W.
Muhlestein J.B.
Munzel T.
Musunuru K.
Nahrstaedt J.
Nelson C.P.
Nothen M.M.
Olivieri O.
Patel R.S.
Patterson C.C.
Peters A.
Peyvandi F.
Qu L.
Quyyumi A.A.
Rader D.J.
Rallidis L.S.
Rice C.
Rosendaal F.R.
Rubin D.
Salomaa V.
Sampietro M.L.
Sandhu M.S.
Schadt E.
Schafer A.
Schillert A.
Schreiber S.
Schrezenmeir J.
Schwartz S.M.
Siscovick D.S.
Sivananthan M.
Sivapalaratnam S.
Smith A.
Smith T.B.
Snoep J.D.
Soranzo N.
Spertus J.A.
Stark K.
Stirrups K.
Stoll M.
Tang W.H.
Tennstedt S.
Thorgeirsson G.
Thorleifsson G.
Tomaszewski M.
Uitterlinden A.G.
van Rij A.M.
Voight B.F.
Wareham N.J.
Wells G.A.
Wichmann H.E.
Wild P.S.
Willenborg C.
Witteman J.C.
Wright B.J.
Ye S.
Zeller T.
Ziegler A.
Cambien F.
Goodall A.H.
Cupples L.A.
Quertermous T.
Marz W.
Hengstenberg C.
Blankenberg S.
Ouwehand W.H.
Hall A.S.
Deloukas P.
Thompson J.R.
Stefansson K.
Roberts R.
Thorsteinsdottir U.
O'Donnell C.J.
McPherson R.
Erdmann J.
Samani N.J.

Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease.

In the genome-wide association studies evaluating lipid traits, a linear regression analysis was performed to evaluate how lipid levels were related to CHD risk. Notably, significant associations with CHD risk were found for LDL-C effect size (Pearson r = 0.74; p = 7 × 10⁻⁶) and triglyceride effect size (Pearson r = 0.46; p = 0.02) but not for HDL-C effect size (r = 0.0009; p = 0.99).

¹⁷

Willer C.J.
Schmidt E.M.
Sengupta S.
Peloso G.M.
Gustafsson S.
Kanoni S.
Ganna A.
Chen J.
Buchkovich M.L.
Mora S.
Beckmann J.S.
Bragg-Gresham J.L.
Chang H.Y.
Demirkan A.
Den Hertog H.M.
Do R.
Donnelly L.A.
Ehret G.B.
Esko T.
Feitosa M.F.
Ferreira T.
Fischer K.
Fontanillas P.
Fraser R.M.
Freitag D.F.
Gurdasani D.
Heikkila K.
Hypponen E.
Isaacs A.
Jackson A.U.
Johansson A.
Johnson T.
Kaakinen M.
Kettunen J.
Kleber M.E.
Li X.
Luan J.
Lyytikainen L.P.
Magnusson P.K.
Mangino M.
Mihailov E.
Montasser M.E.
Muller-Nurasyid M.
Nolte I.M.
O'Connell J.R.
Palmer C.D.
Perola M.
Petersen A.K.
Sanna S.
Saxena R.
Service S.K.
Shah S.
Shungin D.
Sidore C.
Song C.
Strawbridge R.J.
Surakka I.
Tanaka T.
Teslovich T.M.
Thorleifsson G.
Van den Herik E.G.
Voight B.F.
Volcik K.A.
Waite L.L.
Wong A.
Wu Y.
Zhang W.
Absher D.
Asiki G.
Barroso I.
Been L.F.
Bolton J.L.
Bonnycastle L.L.
Brambilla P.
Burnett M.S.
Cesana G.
Dimitriou M.
Doney A.S.
Doring A.
Elliott P.
Epstein S.E.
Eyjolfsson G.I.
Gigante B.
Goodarzi M.O.
Grallert H.
Gravito M.L.
Groves C.J.
Hallmans G.
Hartikainen A.L.
Hayward C.
Hernandez D.
Hicks A.A.
Holm H.
Hung Y.J.
Illig T.
Jones M.R.
Kaleebu P.
Kastelein J.J.
Khaw K.T.
Kim E.
Klopp N.
Komulainen P.
Kumari M.
Langenberg C.
Lehtimaki T.
Lin S.Y.
Lindstrom J.
Loos R.J.
Mach F.
McArdle W.L.
Meisinger C.
Mitchell B.D.
Muller G.
Nagaraja R.
Narisu N.
Nieminen T.V.
Nsubuga R.N.
Olafsson I.
Ong K.K.
Palotie A.
Papamarkou T.
Pomilla C.
Pouta A.
Rader D.J.
Reilly M.P.
Ridker P.M.
Rivadeneira F.
Rudan I.
Ruokonen A.
Samani N.
Scharnagl H.
Seeley J.
Silander K.
Stancakova A.
Stirrups K.
Swift A.J.
Tiret L.
Uitterlinden A.G.
van Pelt L.J.
Vedantam S.
Wainwright N.
Wijmenga C.
Wild S.H.
Willemsen G.
Wilsgaard T.
Wilson J.F.
Young E.H.
Zhao J.H.
Adair L.S.
Arveiler D.
Assimes T.L.
Bandinelli S.
Bennett F.
Bochud M.
Boehm B.O.
Boomsma D.I.
Borecki I.B.
Bornstein S.R.
Bovet P.
Burnier M.
Campbell H.
Chakravarti A.
Chambers J.C.
Chen Y.D.
Collins F.S.
Cooper R.S.
Danesh J.
Dedoussis G.
de Faire U.
Feranil A.B.
Ferrieres J.
Ferrucci L.
Freimer N.B.
Gieger C.
Groop L.C.
Gudnason V.
Gyllensten U.
Hamsten A.
Harris T.B.
Hingorani A.
Hirschhorn J.N.
Hofman A.
Hovingh G.K.
Hsiung C.A.
Humphries S.E.
Hunt S.C.
Hveem K.
Iribarren C.
Jarvelin M.R.
Jula A.
Kahonen M.
Kaprio J.
Kesaniemi A.
Kivimaki M.
Kooner J.S.
Koudstaal P.J.
Krauss R.M.
Kuh D.
Kuusisto J.
Kyvik K.O.
Laakso M.
Lakka T.A.
Lind L.
Lindgren C.M.
Martin N.G.
Marz W.
McCarthy M.I.
McKenzie C.A.
Meneton P.
Metspalu A.
Moilanen L.
Morris A.D.
Munroe P.B.
Njolstad I.
Pedersen N.L.
Power C.
Pramstaller P.P.
Price J.F.
Psaty B.M.
Quertermous T.
Rauramaa R.
Saleheen D.
Salomaa V.
Sanghera D.K.
Saramies J.
Schwarz P.E.
Sheu W.H.
Shuldiner A.R.
Siegbahn A.
Spector T.D.
Stefansson K.
Strachan D.P.
Tayo B.O.
Tremoli E.
Tuomilehto J.
Uusitupa M.
van Duijn C.M.
Vollenweider P.
Wallentin L.
Wareham N.J.
Whitfield J.B.
Wolffenbuttel B.H.
Ordovas J.M.
Boerwinkle E.
Palmer C.N.
Thorsteinsdottir U.
Chasman D.I.
Rotter J.I.
Franks P.W.
Ripatti S.
Cupples L.A.
Sandhu M.S.
Rich S.S.
Boehnke M.
Deloukas P.

Discovery and refinement of loci associated with lipid levels.

Because most SNPs affect multiple lipid fractions, a multivariate analysis was performed on the 185 SNPs that had moderate to strong effects on triglyceride levels; the triglyceride effect size was strongly associated with CHD after adjusting for both LDL-C and HDL-C effect sizes (Table 2).

¹⁸

Do R.
Willer C.J.
Schmidt E.M.
Sengupta S.
Gao C.
Peloso G.M.
Gustafsson S.
Kanoni S.
Ganna A.
Chen J.
Buchkovich M.L.
Mora S.
Beckmann J.S.
Bragg-Gresham J.L.
Chang H.Y.
Demirkan A.
Den Hertog H.M.
Donnelly L.A.
Ehret G.B.
Esko T.
Feitosa M.F.
Ferreira T.
Fischer K.
Fontanillas P.
Fraser R.M.
Freitag D.F.
Gurdasani D.
Heikkila K.
Hypponen E.
Isaacs A.
Jackson A.U.
Johansson A.
Johnson T.
Kaakinen M.
Kettunen J.
Kleber M.E.
Li X.
Luan J.
Lyytikainen L.P.
Magnusson P.K.
Mangino M.
Mihailov E.
Montasser M.E.
Muller-Nurasyid M.
Nolte I.M.
O'Connell J.R.
Palmer C.D.
Perola M.
Petersen A.K.
Sanna S.
Saxena R.
Service S.K.
Shah S.
Shungin D.
Sidore C.
Song C.
Strawbridge R.J.
Surakka I.
Tanaka T.
Teslovich T.M.
Thorleifsson G.
Van den Herik E.G.
Voight B.F.
Volcik K.A.
Waite L.L.
Wong A.
Wu Y.
Zhang W.
Absher D.
Asiki G.
Barroso I.
Been L.F.
Bolton J.L.
Bonnycastle L.L.
Brambilla P.
Burnett M.S.
Cesana G.
Dimitriou M.
Doney A.S.
Doring A.
Elliott P.
Epstein S.E.
Eyjolfsson G.I.
Gigante B.
Goodarzi M.O.
Grallert H.
Gravito M.L.
Groves C.J.
Hallmans G.
Hartikainen A.L.
Hayward C.
Hernandez D.
Hicks A.A.
Holm H.
Hung Y.J.
Illig T.
Jones M.R.
Kaleebu P.
Kastelein J.J.
Khaw K.T.
Kim E.
Klopp N.
Komulainen P.
Kumari M.
Langenberg C.
Lehtimaki T.
Lin S.Y.
Lindstrom J.
Loos R.J.
Mach F.
McArdle W.L.
Meisinger C.
Mitchell B.D.
Muller G.
Nagaraja R.
Narisu N.
Nieminen T.V.
Nsubuga R.N.
Olafsson I.
Ong K.K.
Palotie A.
Papamarkou T.
Pomilla C.
Pouta A.
Rader D.J.
Reilly M.P.
Ridker P.M.
Rivadeneira F.
Rudan I.
Ruokonen A.
Samani N.
Scharnagl H.
Seeley J.
Silander K.
Stancakova A.
Stirrups K.
Swift A.J.
Tiret L.
Uitterlinden A.G.
van Pelt L.J.
Vedantam S.
Wainwright N.
Wijmenga C.
Wild S.H.
Willemsen G.
Wilsgaard T.
Wilson J.F.
Young E.H.
Zhao J.H.
Adair L.S.
Arveiler D.
Assimes T.L.
Bandinelli S.
Bennett F.
Bochud M.
Boehm B.O.
Boomsma D.I.
Borecki I.B.
Bornstein S.R.
Bovet P.
Burnier M.
Campbell H.
Chakravarti A.
Chambers J.C.
Chen Y.D.
Collins F.S.
Cooper R.S.
Danesh J.
Dedoussis G.
de Faire U.
Feranil A.B.
Ferrieres J.
Ferrucci L.
Freimer N.B.
Gieger C.
Groop L.C.
Gudnason V.
Gyllensten U.
Hamsten A.
Harris T.B.
Hingorani A.
Hirschhorn J.N.
Hofman A.
Hovingh G.K.
Hsiung C.A.
Humphries S.E.
Hunt S.C.
Hveem K.
Iribarren C.
Jarvelin M.R.
Jula A.
Kahonen M.
Kaprio J.
Kesaniemi A.
Kivimaki M.
Kooner J.S.
Koudstaal P.J.
Krauss R.M.
Kuh D.
Kuusisto J.
Kyvik K.O.
Laakso M.
Lakka T.A.
Lind L.
Lindgren C.M.
Martin N.G.
Marz W.
McCarthy M.I.
McKenzie C.A.
Meneton P.
Metspalu A.
Moilanen L.
Morris A.D.
Munroe P.B.
Njolstad I.
Pedersen N.L.
Power C.
Pramstaller P.P.
Price J.F.
Psaty B.M.
Quertermous T.
Rauramaa R.
Saleheen D.
Salomaa V.
Sanghera D.K.
Saramies J.
Schwarz P.E.
Sheu W.H.
Shuldiner A.R.
Siegbahn A.
Spector T.D.
Stefansson K.
Strachan D.P.
Tayo B.O.
Tremoli E.
Tuomilehto J.
Uusitupa M.
van Duijn C.M.
Vollenweider P.
Wallentin L.
Wareham N.J.
Whitfield J.B.
Wolffenbuttel B.H.
Altshuler D.
Ordovas J.M.
Boerwinkle E.
Palmer C.N.
Thorsteinsdottir U.
Chasman D.I.
Rotter J.I.
Franks P.W.
Ripatti S.
Cupples L.A.
Sandhu M.S.
Rich S.S.

Common variants associated with plasma triglycerides and risk for coronary artery disease.

Similar analyses showed that LDL-C (p = 2 × 10⁻²²), but not HDL-C (p = 0.35), was associated with CHD after correcting for the other corresponding lipids.

Extending our understanding of the genetic contributions of lipid-related traits beyond the genomic studies of DNA sequence variants, an epigenome-wide association study examined the relation between fasting blood lipid levels and differential methylation sites.

²⁷

Irvin M.R.
Zhi D.
Joehanes R.
Mendelson M.
Aslibekyan S.
Claas S.A.
Thibeault K.S.
Patel N.
Day K.
Jones L.W.
Liang L.
Chen B.H.
Yao C.
Tiwari H.K.
Ordovas J.M.
Levy D.
Absher D.
Arnett D.K.

Epigenome-wide association study of fasting blood lipids in the Genetics of Lipid-lowering Drugs and Diet Network study.

In this study, methylation at 4 sites of intron 1 of carnitine palmitoyltransferase 1A was found to be strongly associated with triglyceride and VLDL cholesterol levels and may represent novel loci involved in the prevention of CVD.

²⁷

Irvin M.R.
Zhi D.
Joehanes R.
Mendelson M.
Aslibekyan S.
Claas S.A.
Thibeault K.S.
Patel N.
Day K.
Jones L.W.
Liang L.
Chen B.H.
Yao C.
Tiwari H.K.
Ordovas J.M.
Levy D.
Absher D.
Arnett D.K.

Epigenome-wide association study of fasting blood lipids in the Genetics of Lipid-lowering Drugs and Diet Network study.

Mendelian randomization studies

Mendelian randomization studies are based on the segregation and independent assortment of specific genotypes according to the laws of Mendelian genetics.

²⁸

Taylor A.E.
Davies N.M.
Ware J.J.
VanderWeele T.
Smith G.D.
Munafo M.R.

Mendelian randomization in health research: using appropriate genetic variants and avoiding biased estimates.

In these studies, subjects with specific genotypes that predispose to a specific effect (e.g., hypertriglyceridemia) are compared with subjects without those genotypes. Because these studies are not affected by confounding factors seen in observational epidemiologic studies, they can provide robust evidence for the causal involvement of a specific mechanism in a disease state. Mendelian randomization studies have been conducted that evaluate whether factors involved in TRL metabolism are causally associated with atherosclerosis and CHD (Table 3).

Several Mendelian randomization studies were conducted using data from 3 Copenhagen population cohorts. In the first study, 3 common APOA5 variants were used to define 10 common genotype combinations, which were associated with substantial stepwise increases in nonfasting triglyceride levels and calculated remnant cholesterol levels (which is the cholesterol content of TRLs), and with corresponding increases in risk of MI.

¹⁹

Jorgensen A.B.
Frikke-Schmidt R.
West A.S.
Grande P.
Nordestgaard B.G.
Tybjaerg-Hansen A.

Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction.

For a doubling of nonfasting triglyceride levels and calculated remnant cholesterol levels, the causal odds ratios for risk of MI were 1.94 (95% CI 1.40 to 1.85) and 2.23 (95% CI 1.48 to 3.35), respectively. Studies 2 and 3 evaluated genotypes associated with increasing nonfasting remnant cholesterol levels and differed based on which APOA5 and LPL genotypes were used to define increasing remnant cholesterol levels.

²⁰

Varbo A.
Benn M.
Tybjaerg-Hansen A.
Jorgensen A.B.
Frikke-Schmidt R.
Nordestgaard B.G.

Remnant cholesterol as a causal risk factor for ischemic heart disease.

^,

²¹

Varbo A.
Benn M.
Tybjaerg-Hansen A.
Nordestgaard B.G.

Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation.

Both studies found that remnant cholesterol levels were highly correlated with nonfasting triglyceride levels and with observed CHD risk (Table 3). A subsequent Mendelian randomization study using data from the Copenhagen City Heart Study found that genetic variants in LPL resulted in reduced triglyceride levels, and that a higher number of triglyceride-decreasing LPL alleles was associated with increased survival (p = 0.004).

²²

Thomsen M.
Varbo A.
Tybjaerg-Hansen A.
Nordestgaard B.G.

Low nonfasting triglycerides and reduced all-cause mortality: a Mendelian randomization study.

To overcome limitations in which only a limited number of variants are used, a Mendelian randomization meta-analysis was conducted using data from 17 studies involving 62,199 participants and 12,099 CHD events.

²³

Holmes M.V.
Asselbergs F.W.
Palmer T.M.
Drenos F.
Lanktree M.B.
Nelson C.P.
Dale C.E.
Padmanabhan S.
Finan C.
Swerdlow D.I.
Tragante V.
van Iperen E.P.
Sivapalaratnam S.
Shah S.
Elbers C.C.
Shah T.
Engmann J.
Giambartolomei C.
White J.
Zabaneh D.
Sofat R.
McLachlan S.
Doevendans P.A.
Balmforth A.J.
Hall A.S.
North K.E.
Almoguera B.
Hoogeveen R.C.
Cushman M.
Fornage M.
Patel S.R.
Redline S.
Siscovick D.S.
Tsai M.Y.
Karczewski K.J.
Hofker M.H.
Verschuren W.M.
Bots M.L.
van der Schouw Y.T.
Melander O.
Dominiczak A.F.
Morris R.
Ben-Shlomo Y.
Price J.
Kumari M.
Baumert J.
Peters A.
Thorand B.
Koenig W.
Gaunt T.R.
Humphries S.E.
Clarke R.
Watkins H.
Farrall M.
Wilson J.G.
Rich S.S.
de Bakker P.I.
Lange L.A.
Davey S.G.
Reiner A.P.
Talmud P.J.
Kivimaki M.
Lawlor D.A.
Dudbridge F.
Samani N.J.
Keating B.J.
Hingorani A.D.
Casas J.P.

Mendelian randomization of blood lipids for coronary heart disease.

Unrestricted allele scores were determined based on all SNPs that had established associations with triglycerides, HDL-C, or LDL-C, and then restricted allele scores were generated in which SNPs were excluded if they were also associated with either of the 2 other lipids. For triglycerides, both the unrestricted allele score based on 67 SNPs and the restricted allele score based on 27 SNPs were significantly associated with CHD (Table 3). Allele scores for LDL-C but not HDL-C were significantly associated with CHD. However, for HDL-C, the restricted allele score was not associated with CHD; the odds ratio for a 1 mmol/L (39 mg/dl) genetic increment in HDL-C level was 0.91 (95% CI 0.42 to 1.98).

Taken together, the genetic data for triglycerides and TRLs align with the epidemiologic and clinical data and support a causative role for these lipids in ASCVD and compare favorably with those linking LDL-C with ASCVD, in contrast to those for HDL-C that did not show a causative role in CV disease.

²⁹

Voight B.F.
Peloso G.M.
Orho-Melander M.
Frikke-Schmidt R.
Barbalic M.
Jensen M.K.
Hindy G.
Holm H.
Ding E.L.
Johnson T.
Schunkert H.
Samani N.J.
Clarke R.
Hopewell J.C.
Thompson J.F.
Li M.
Thorleifsson G.
Newton-Cheh C.
Musunuru K.
Pirruccello J.P.
Saleheen D.
Chen L.
Stewart A.
Schillert A.
Thorsteinsdottir U.
Thorgeirsson G.
Anand S.
Engert J.C.
Morgan T.
Spertus J.
Stoll M.
Berger K.
Martinelli N.
Girelli D.
McKeown P.P.
Patterson C.C.
Epstein S.E.
Devaney J.
Burnett M.S.
Mooser V.
Ripatti S.
Surakka I.
Nieminen M.S.
Sinisalo J.
Lokki M.L.
Perola M.
Havulinna A.
de Faire U.
Gigante B.
Ingelsson E.
Zeller T.
Wild P.
de Bakker P.I.
Klungel O.H.
Maitland-van der Zee A.H.
Peters B.J.
de B.A.
Grobbee D.E.
Kamphuisen P.W.
Deneer V.H.
Elbers C.C.
Onland-Moret N.C.
Hofker M.H.
Wijmenga C.
Verschuren W.M.
Boer J.M.
van der Schouw Y.T.
Rasheed A.
Frossard P.
Demissie S.
Willer C.
Do R.
Ordovas J.M.
Abecasis G.R.
Boehnke M.
Mohlke K.L.
Daly M.J.
Guiducci C.
Burtt N.P.
Surti A.
Gonzalez E.
Purcell S.
Gabriel S.
Marrugat J.
Peden J.
Erdmann J.
Diemert P.
Willenborg C.
Konig I.R.
Fischer M.
Hengstenberg C.
Ziegler A.
Buysschaert I.
Lambrechts D.
Van de Werf F.
Fox K.A.
El Mokhtari N.E.
Rubin D.
Schrezenmeir J.
Schreiber S.
Schafer A.
Danesh J.
Blankenberg S.
Roberts R.
McPherson R.
Watkins H.
Hall A.S.
Overvad K.
Rimm E.
Boerwinkle E.
Tybjaerg-Hansen A.
Cupples L.A.
Reilly M.P.
Melander O.
Mannucci P.M.
Ardissino D.
Siscovick D.
Elosua R.
Stefansson K.
O'Donnell C.J.
Salomaa V.
Rader D.J.
Peltonen L.
Schwartz S.M.
Altshuler D.
Kathiresan S.

Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study.

^,

³⁰

Frikke-Schmidt R.
Nordestgaard B.G.
Stene M.C.
Sethi A.A.
Remaley A.T.
Schnohr P.
Grande P.
Tybjaerg-Hansen A.

Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease.

^,

³¹

Johannsen T.H.
Kamstrup P.R.
Andersen R.V.
Jensen G.B.
Sillesen H.
Tybjaerg-Hansen A.
Nordestgaard B.G.

Hepatic lipase, genetically elevated high-density lipoprotein, and risk of ischemic cardiovascular disease.

The latter finding is notable given that HDL-C–increasing drugs have failed to improve CV outcomes in large clinical studies.

³²

Barter P.J.
Caulfield M.
Eriksson M.
Grundy S.M.
Kastelein J.J.
Komajda M.
Lopez-Sendon J.
Mosca L.
Tardif J.C.
Waters D.D.
Shear C.L.
Revkin J.H.
Buhr K.A.
Fisher M.R.
Tall A.R.
Brewer B.

Effects of torcetrapib in patients at high risk for coronary events.

^,

³³

Schwartz G.G.
Olsson A.G.
Abt M.
Ballantyne C.M.
Barter P.J.
Brumm J.
Chaitman B.R.
Holme I.M.
Kallend D.
Leiter L.A.
Leitersdorf E.
McMurray J.J.
Mundl H.
Nicholls S.J.
Shah P.K.
Tardif J.C.
Wright R.S.

Effects of dalcetrapib in patients with a recent acute coronary syndrome.

Clinical implications

Statins are widely used as an adjunct to diet and exercise in the first-line treatment of patients with lipid abnormalities. Statins substantially reduce LDL-C levels and may also help to lower triglyceride levels. However, the effects of statins on triglyceride levels are often insufficient, and therefore a triglyceride-lowering agent may need to be added to statin therapy if triglyceride levels remain high. Treatment options include omega-3 fatty acids, niacin, and fibrates.

Several prescription omega-3 fatty acid products are available; each is currently approved as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia (≥500 mg/dl).

³⁴

Hilleman D.
Smer A.

Prescription omega-3 fatty acid products and dietary supplements are not interchangeable.

Most prescription omega-3 fatty acid products (omega-3-acid ethyl esters [Lovaza; GlaxoSmithKline, Research Triangle Park, North Carolina]; omega-3-acid ethyl esters A [Omtryg; Trygg Pharma, Arlington, Virginia]; and omega-3-carboxylic acids [Epanova; AstraZeneca, Wilmington, Delaware]) contain a mixture of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).

³⁴

Hilleman D.
Smer A.

Prescription omega-3 fatty acid products and dietary supplements are not interchangeable.

However, icosapent ethyl (Vascepa; Amarin Pharma Inc., Bedminster, New Jersey) is a high-purity prescription formulation containing the ethyl ester of EPA.

³⁵

Google Scholar

In clinical trials, all prescription omega-3 fatty acids significantly reduced triglyceride levels in hypertriglyceridemic patients in the absence or presence of background statin therapy.

³⁶

Harris W.S.
Ginsberg H.N.
Arunakul N.
Shachter N.S.
Windsor S.L.
Adams M.
Berglund L.
Osmundsen K.

Safety and efficacy of Omacor in severe hypertriglyceridemia.

^,

³⁷

Pownall H.J.
Brauchi D.
Kilinc C.
Osmundsen K.
Pao Q.
Payton-Ross C.
Gotto Jr., A.M.
Ballantyne C.M.

Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins.

^,

³⁸

Davidson M.H.
Stein E.A.
Bays H.E.
Maki K.C.
Doyle R.T.
Shalwitz R.A.
Ballantyne C.M.
Ginsberg H.N.

Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.

^,

³⁹

Bays H.E.
Ballantyne C.M.
Kastelein J.J.
Isaacsohn J.L.
Braeckman R.A.
Soni P.N.

Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial).

^,

⁴⁰

Ballantyne C.M.
Bays H.E.
Kastelein J.J.
Stein E.
Isaacsohn J.L.
Braeckman R.A.
Soni P.N.

Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).

^,

⁴¹

Kastelein J.J.P.
Maki K.C.
Susekov A.
Ezhov M.
Nordestgaard B.G.
Machielse B.N.
Kling D.
Davidson M.H.

Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial.

^,

⁴²

Maki K.C.
Orloff D.G.
Nicholls S.J.
Dunbar R.L.
Roth E.M.
Curcio D.
Johnson J.
Kling D.
Davidson M.H.

A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial).

^,

⁴³

Google Scholar

^,

⁴⁴

Google Scholar

^,

⁴⁵

Google Scholar

Notably, the products containing both EPA and DHA were found in clinical trials to increase LDL-C levels, an unwanted potential effect in treating patients with lipid abnormalities.

³⁴

Hilleman D.
Smer A.

Prescription omega-3 fatty acid products and dietary supplements are not interchangeable.

In contrast, icosapent ethyl did not increase LDL-C levels compared with placebo in clinical trials.

³⁹

Bays H.E.
Ballantyne C.M.
Kastelein J.J.
Isaacsohn J.L.
Braeckman R.A.
Soni P.N.

Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial).

^,

⁴⁰

Ballantyne C.M.
Bays H.E.
Kastelein J.J.
Stein E.
Isaacsohn J.L.
Braeckman R.A.
Soni P.N.

Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).

Icosapent ethyl, as well as products containing both EPA and DHA, has also shown beneficial effects on the levels of other atherogenic lipid parameters discussed herein, including non–HDL-C, VLDL cholesterol, and/or TRLs.

³⁷

Pownall H.J.
Brauchi D.
Kilinc C.
Osmundsen K.
Pao Q.
Payton-Ross C.
Gotto Jr., A.M.
Ballantyne C.M.

Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins.

^,

³⁸

Davidson M.H.
Stein E.A.
Bays H.E.
Maki K.C.
Doyle R.T.
Shalwitz R.A.
Ballantyne C.M.
Ginsberg H.N.

Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.

^,

³⁹

Bays H.E.
Ballantyne C.M.
Kastelein J.J.
Isaacsohn J.L.
Braeckman R.A.
Soni P.N.

Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial).

^,

⁴⁰

Ballantyne C.M.
Bays H.E.
Kastelein J.J.
Stein E.
Isaacsohn J.L.
Braeckman R.A.
Soni P.N.

Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).

^,

⁴²

Maki K.C.
Orloff D.G.
Nicholls S.J.
Dunbar R.L.
Roth E.M.
Curcio D.
Johnson J.
Kling D.
Davidson M.H.

A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial).

^,

⁴⁶

Ballantyne C.M.
Bays H.E.
Braeckman R.A.
Philip S.
Stirtan W.G.
Doyle Jr., R.T.
Soni P.N.
Juliano R.A.

Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies.

Google Scholar

Omega-3 fatty acid prescription products have well-established favorable safety and tolerability profiles.

³⁴

Hilleman D.
Smer A.

Prescription omega-3 fatty acid products and dietary supplements are not interchangeable.

In contrast, niacin and fibrates, although effective in reducing triglyceride levels and other lipid parameters, are associated with tolerability issues that may compromise treatment. Niacin causes flushing, which many patients find intolerable, and also has the potential to increase serum glucose and cause liver toxicity or myopathy, particularly when coadministered with a statin.

⁴⁷

Ito M.K.

Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature.

Fibrates may blunt the beneficial effects of statins on LDL-C, particularly in patients with atherogenic dyslipidemia,

⁴⁸

Davidson M.H.
Rosenson R.S.
Maki K.C.
Nicholls S.J.
Ballantyne C.M.
Mazzone T.
Carlson D.M.
Williams L.A.
Kelly M.T.
Camp H.S.
Lele A.
Stolzenbach J.C.

Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST).

and like niacin, has the potential to cause myopathy when used in combination with a statin.

⁴⁷

Ito M.K.

Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature.

The use of niacin or fibrates in combination with a statin has recently been removed from the labels of several products because of the lack of data showing CV benefit with these combinations.

The benefits of omega-3 fatty acids may extend beyond triglyceride lowering, including effects on vascular and cardiac hemodynamics, arrhythmia, inflammation, endothelial function, thrombosis, and production of inflammation-resolving mediators such as resolvins and protectins.

⁴⁹

Mozaffarian D.
Wu J.H.

Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events.

Although both EPA and DHA may contribute to health benefits of omega-3 fatty acids, it is also important to note that EPA, as a 20-carbon fatty acid, but not DHA (a 22-carbon fatty acid), can displace arachidonic acid (also a 20-carbon fatty acid) in metabolic pathways and thus antagonize arachidonic-mediated inflammatory reactions.

⁵⁰

Manku MS, Best practices: why EPA only? Understanding the distinctions between high-dose prescription EPA-only drug intervention for treating disease versus omega-3 dietary supplementation for promotion of health. Intern Med News. December 2015. Supplement.

Google Scholar

Indeed, EPA specifically has been shown to have pleiotropic effects that beneficially influence multiple steps in atherosclerosis development and progression including endothelial dysfunction, oxidative stress, foam cell formation, inflammation and cytokine effects, plaque formation and progression, platelet aggregation, thrombus formation, and plaque rupture.

⁵¹

Borow K.M.
Nelson J.R.
Mason R.P.

Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis.

Recent studies support the concept that add-on therapy to a statin can reduce residual risk and provide CV benefit.

⁵²

Cannon C.P.
Blazing M.A.
Giugliano R.P.
McCagg A.
White J.A.
Theroux P.
Darius H.
Lewis B.S.
Ophuis T.O.
Jukema J.W.
De Ferrari G.M.
Ruzyllo W.
De L.P.
Im K.
Bohula E.A.
Reist C.
Wiviott S.D.
Tershakovec A.M.
Musliner T.A.
Braunwald E.
Califf R.M.

Ezetimibe added to statin therapy after acute coronary syndromes.

^,

⁵³

Blom D.J.
Hala T.
Bolognese M.
Lillestol M.J.
Toth P.D.
Burgess L.
Ceska R.
Roth E.
Koren M.J.
Ballantyne C.M.
Monsalvo M.L.
Tsirtsonis K.
Kim J.B.
Scott R.
Wasserman S.M.
Stein E.A.

A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.

^,

⁵⁴

Robinson J.G.
Farnier M.
Krempf M.
Bergeron J.
Luc G.
Averna M.
Stroes E.S.
Langslet G.
Raal F.J.
Shahawy M.E.
Koren M.J.
Lepor N.E.
Lorenzato C.
Pordy R.
Chaudhari U.
Kastelein J.J.

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.

^,

⁵⁵

Sabatine M.S.
Giugliano R.P.
Wiviott S.D.
Raal F.J.
Blom D.J.
Robinson J.
Ballantyne C.M.
Somaratne R.
Legg J.
Wasserman S.M.
Scott R.
Koren M.J.
Stein E.A.

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

Two large outcome trials are testing the triglyceride-lowering hypothesis with prescription omega-3 fatty acid products in statin-treated patients at high CV risk. The Reduction of Cardiovascular Events with EPA-Intervention Trial (REDUCE-IT; NCT01492361) is evaluating 4 g/day icosapent ethyl (prescription EPA only), whereas the Statin Residual Risk Reduction With Epanova in High CV Risk Patients With Hypertriglyceridemia study (STRENGTH; NCT02104817) is evaluating omega-3-carboxylic acids (prescription EPA plus DHA). The primary end point is a composite including CV death, MI, stroke, revascularization, and hospitalization for unstable angina. Data from these clinical outcome trials will help to elucidate whether high-dose prescription omega-3 fatty acid products reduce ASCVD in high-risk, statin-treated patients, such as those commonly encountered in clinical practice.

Acknowledgment

Medical review, scientific reference checks, and associated assistance were provided by Joy Bronson and Christina Copland, PhD, MPH, of Amarin Pharma Inc., Bedminster, New Jersey, USA. Medical writing assistance was provided by Peloton Advantage, LLC, Parsippany, New Jersey, USA, and was funded by Amarin Pharma Inc .

Disclosures

Dr. Budoff has received research/grant support from General Electric and is a member of the speaker's bureau for Amarin Pharma Inc.

References

- Boullart A.C.
- de G.J.
- Stalenhoef A.F.
Serum triglycerides and risk of cardiovascular disease.
Biochim Biophys Acta. 2012; 1821: 867-875
View in Article
- Miller M.
- Stone N.J.
- Ballantyne C.
- Bittner V.
- Criqui M.H.
- Ginsberg H.N.
- Goldberg A.C.
- Howard W.J.
- Jacobson M.S.
- Kris-Etherton P.M.
- Lennie T.A.
- Levi M.
- Mazzone T.
- Pennathur S.
Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association.
Circulation. 2011; 123: 2292-2333
View in Article
- Khetarpal S.A.
- Rader D.J.
Triglyceride-rich lipoproteins and coronary artery disease risk: new insights from human genetics.
Arterioscler Thromb Vasc Biol. 2015; 35: e3-e9
View in Article
- Wang H.
- Eckel R.H.
Lipoprotein lipase: from gene to obesity.
Am J Physiol Endocrinol Metab. 2009; 297: E271-E288
View in Article
- Jacobson T.A.
- Ito M.K.
- Maki K.C.
- Orringer C.E.
- Bays H.E.
- Jones P.H.
- McKenney J.M.
- Grundy S.M.
- Gill E.A.
- Wild R.A.
- Wilson D.P.
- Brown W.V.
National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1-executive summary.
J Clin Lipidol. 2014; 8: 473-488
View in Article
- May H.T.
- Nelson J.R.
- Lirette S.T.
- Kulkarni K.R.
- Anderson J.L.
- Griswold M.E.
- Horne B.D.
- Correa A.
- Muhlestein J.B.
The utility of the apolipoprotein A1 remnant ratio in predicting incidence coronary heart disease in a primary prevention cohort: the Jackson Heart Study.
Eur J Prev Cardiol. 2016; 23: 769-776
View in Article
- Pollin T.I.
- Damcott C.M.
- Shen H.
- Ott S.H.
- Shelton J.
- Horenstein R.B.
- Post W.
- McLenithan J.C.
- Bielak L.F.
- Peyser P.A.
- Mitchell B.D.
- Miller M.
- O'Connell J.R.
- Shuldiner A.R.
A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection.
Science. 2008; 322: 1702-1705
View in Article
- Jorgensen A.B.
- Frikke-Schmidt R.
- Nordestgaard B.G.
- Tybjaerg-Hansen A.
Loss-of-function mutations in APOC3 and risk of ischemic vascular disease.
N Engl J Med. 2014; 371: 32-41
View in Article
- Crosby J.
- Peloso G.M.
- Auer P.L.
- Crosslin D.R.
- Stitziel N.O.
- Lange L.A.
- Lu Y.
- Tang Z.Z.
- Zhang H.
- Hindy G.
- Masca N.
- Stirrups K.
- Kanoni S.
- Do R.
- Jun G.
- Hu Y.
- Kang H.M.
- Xue C.
- Goel A.
- Farrall M.
- Duga S.
- Merlini P.A.
- Asselta R.
- Girelli D.
- Olivieri O.
- Martinelli N.
- Yin W.
- Reilly D.
- Speliotes E.
- Fox C.S.
- Hveem K.
- Holmen O.L.
- Nikpay M.
- Farlow D.N.
- Assimes T.L.
- Franceschini N.
- Robinson J.
- North K.E.
- Martin L.W.
- DePristo M.
- Gupta N.
- Escher S.A.
- Jansson J.H.
- Van Z.N.
- Palmer C.N.
- Wareham N.
- Koch W.
- Meitinger T.
- Peters A.
- Lieb W.
- Erbel R.
- Konig I.R.
- Kruppa J.
- Degenhardt F.
- Gottesman O.
- Bottinger E.P.
- O'Donnell C.J.
- Psaty B.M.
- Ballantyne C.M.
- Abecasis G.
- Ordovas J.M.
- Melander O.
- Watkins H.
- Orho-Melander M.
- Ardissino D.
- Loos R.J.
- McPherson R.
- Willer C.J.
- Erdmann J.
- Hall A.S.
- Samani N.J.
- Deloukas P.
- Schunkert H.
- Wilson J.G.
- Kooperberg C.
- Rich S.S.
- Tracy R.P.
- Lin D.Y.
- Altshuler D.
- Gabriel S.
- Nickerson D.A.
- Jarvik G.P.
- Cupples L.A.
- Reiner A.P.
- Boerwinkle E.
- Kathiresan S.
Loss-of-function mutations in APOC3, triglycerides, and coronary disease.
N Engl J Med. 2014; 371: 22-31
View in Article
- Natarajan P.
- Kohli P.
- Baber U.
- Nguyen K.D.
- Sartori S.
- Reilly D.F.
- Mehran R.
- Muntendam P.
- Fuster V.
- Rader D.J.
- Kathiresan S.
Association of APOC3 loss-of-function mutations with plasma lipids and subclinical atherosclerosis.
J Am Coll Cardiol. 2015; 66: 2053-2055
View in Article
- Do R.
- Stitziel N.O.
- Won H.H.
- Jorgensen A.B.
- Duga S.
- Angelica M.P.
- Kiezun A.
- Farrall M.
- Goel A.
- Zuk O.
- Guella I.
- Asselta R.
- Lange L.A.
- Peloso G.M.
- Auer P.L.
- Girelli D.
- Martinelli N.
- Farlow D.N.
- DePristo M.A.
- Roberts R.
- Stewart A.F.
- Saleheen D.
- Danesh J.
- Epstein S.E.
- Sivapalaratnam S.
- Hovingh G.K.
- Kastelein J.J.
- Samani N.J.
- Schunkert H.
- Erdmann J.
- Shah S.H.
- Kraus W.E.
- Davies R.
- Nikpay M.
- Johansen C.T.
- Wang J.
- Hegele R.A.
- Hechter E.
- Marz W.
- Kleber M.E.
- Huang J.
- Johnson A.D.
- Li M.
- Burke G.L.
- Gross M.
- Liu Y.
- Assimes T.L.
- Heiss G.
- Lange E.M.
- Folsom A.R.
- Taylor H.A.
- Olivieri O.
- Hamsten A.
- Clarke R.
- Reilly D.F.
- Yin W.
- Rivas M.A.
- Donnelly P.
- Rossouw J.E.
- Psaty B.M.
- Herrington D.M.
- Wilson J.G.
- Rich S.S.
- Bamshad M.J.
- Tracy R.P.
- Cupples L.A.
- Rader D.J.
- Reilly M.P.
- Spertus J.A.
- Cresci S.
- Hartiala J.
- Tang W.H.
- Hazen S.L.
- Allayee H.
- Reiner A.P.
- Carlson C.S.
- Kooperberg C.
- Jackson R.D.
- Boerwinkle E.
- Lander E.S.
- Schwartz S.M.
- Siscovick D.S.
- McPherson R.
- Tybjaerg-Hansen A.
- Abecasis G.R.
- Watkins H.
- Nickerson D.A.
- Ardissino D.
- Sunyaev S.R.
- O'Donnell C.J.
- Altshuler D.
- Gabriel S.
- Kathiresan S.
Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction.
Nature. 2015; 518: 102-106
View in Article
- Sarwar N.
- Sandhu M.S.
- Ricketts S.L.
- Butterworth A.S.
- Di A.E.
- Boekholdt S.M.
- Ouwehand W.
- Watkins H.
- Samani N.J.
- Saleheen D.
- Lawlor D.
- Reilly M.P.
- Hingorani A.D.
- Talmud P.J.
- Danesh J.
Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies.
Lancet. 2010; 375: 1634-1639
View in Article
- Dewey F.E.
- Gusarova V.
- O'Dushlaine C.
- Gottesman O.
- Trejos J.
- Hunt C.
- Van Hout C.V.
- Habegger L.
- Buckler D.
- Lai K.M.V.
- Leader J.B.
- Murray M.F.
- Ritchie M.D.
- Kirchner H.L.
- Ledbetter D.H.
- Penn J.
- Lopez A.
- Borecki I.B.
- Overton J.D.
- Reid J.G.
- Carey D.J.
- Murphy A.J.
- Yancopoulos G.D.
- Baras A.
- Gromada J.
- Shuldiner A.R.
Inactivating variants in ANGPTL4 and risk of coronary artery disease.
N Engl J Med. 2016; 374: 1123-1133
View in Article
- Stitziel N.
- Stirrups K.
- Masca N.
- Erdmann J.
- Kathiresan S.
- Deloukas P.
- Samani N.J.
- Schunkert H.
Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease.
N Engl J Med. 2016; 374: 1134-1144
View in Article
- Teslovich T.M.
- Musunuru K.
- Smith A.V.
- Edmondson A.C.
- Stylianou I.M.
- Koseki M.
- Pirruccello J.P.
- Ripatti S.
- Chasman D.I.
- Willer C.J.
- Johansen C.T.
- Fouchier S.W.
- Isaacs A.
- Peloso G.M.
- Barbalic M.
- Ricketts S.L.
- Bis J.C.
- Aulchenko Y.S.
- Thorleifsson G.
- Feitosa M.F.
- Chambers J.
- Orho-Melander M.
- Melander O.
- Johnson T.
- Li X.
- Guo X.
- Li M.
- Shin C.Y.
- Jin G.M.
- Jin K.Y.
- Lee J.Y.
- Park T.
- Kim K.
- Sim X.
- Twee-Hee O.R.
- Croteau-Chonka D.C.
- Lange L.A.
- Smith J.D.
- Song K.
- Hua Z.J.
- Yuan X.
- Luan J.
- Lamina C.
- Ziegler A.
- Zhang W.
- Zee R.Y.
- Wright A.F.
- Witteman J.C.
- Wilson J.F.
- Willemsen G.
- Wichmann H.E.
- Whitfield J.B.
- Waterworth D.M.
- Wareham N.J.
- Waeber G.
- Vollenweider P.
- Voight B.F.
- Vitart V.
- Uitterlinden A.G.
- Uda M.
- Tuomilehto J.
- Thompson J.R.
- Tanaka T.
- Surakka I.
- Stringham H.M.
- Spector T.D.
- Soranzo N.
- Smit J.H.
- Sinisalo J.
- Silander K.
- Sijbrands E.J.
- Scuteri A.
- Scott J.
- Schlessinger D.
- Sanna S.
- Salomaa V.
- Saharinen J.
- Sabatti C.
- Ruokonen A.
- Rudan I.
- Rose L.M.
- Roberts R.
- Rieder M.
- Psaty B.M.
- Pramstaller P.P.
- Pichler I.
- Perola M.
- Penninx B.W.
- Pedersen N.L.
- Pattaro C.
- Parker A.N.
- Pare G.
- Oostra B.A.
- O'Donnell C.J.
- Nieminen M.S.
- Nickerson D.A.
- Montgomery G.W.
- Meitinger T.
- McPherson R.
- McCarthy M.I.
- McArdle W.
- Masson D.
- Martin N.G.
- Marroni F.
- Mangino M.
- Magnusson P.K.
- Lucas G.
- Luben R.
- Loos R.J.
- Lokki M.L.
- Lettre G.
- Langenberg C.
- Launer L.J.
- Lakatta E.G.
- Laaksonen R.
- Kyvik K.O.
- Kronenberg F.
- Konig I.R.
- Khaw K.T.
- Kaprio J.
- Kaplan L.M.
- Johansson A.
- Jarvelin M.R.
- Janssens A.C.
- Ingelsson E.
- Igl W.
- Kees H.G.
- Hottenga J.J.
- Hofman A.
- Hicks A.A.
- Hengstenberg C.
- Heid I.M.
- Hayward C.
- Havulinna A.S.
- Hastie N.D.
- Harris T.B.
- Haritunians T.
- Hall A.S.
- Gyllensten U.
- Guiducci C.
- Groop L.C.
- Gonzalez E.
- Gieger C.
- Freimer N.B.
- Ferrucci L.
- Erdmann J.
- Elliott P.
- Ejebe K.G.
- Doring A.
- Dominiczak A.F.
- Demissie S.
- Deloukas P.
- de Geus E.J.
- de Faire U.
- Crawford G.
- Collins F.S.
- Chen Y.D.
- Caulfield M.J.
- Campbell H.
- Burtt N.P.
- Bonnycastle L.L.
- Boomsma D.I.
- Boekholdt S.M.
- Bergman R.N.
- Barroso I.
- Bandinelli S.
- Ballantyne C.M.
- Assimes T.L.
- Quertermous T.
- Altshuler D.
- Seielstad M.
- Wong T.Y.
- Tai E.S.
- Feranil A.B.
- Kuzawa C.W.
- Adair L.S.
- Taylor Jr., H.A.
- Borecki I.B.
- Gabriel S.B.
- Wilson J.G.
- Holm H.
- Thorsteinsdottir U.
- Gudnason V.
- Krauss R.M.
- Mohlke K.L.
- Ordovas J.M.
- Munroe P.B.
- Kooner J.S.
- Tall A.R.
- Hegele R.A.
- Kastelein J.J.
- Schadt E.E.
- Rotter J.I.
- Boerwinkle E.
- Strachan D.P.
- Mooser V.
- Stefansson K.
- Reilly M.P.
- Samani N.J.
- Schunkert H.
- Cupples L.A.
- Sandhu M.S.
- Ridker P.M.
- Rader D.J.
- van Duijn C.M.
- Peltonen L.
- Abecasis G.R.
- Boehnke M.
- Kathiresan S.
Biological, clinical and population relevance of 95 loci for blood lipids.
Nature. 2010; 466: 707-713
View in Article
- Schunkert H.
- Konig I.R.
- Kathiresan S.
- Reilly M.P.
- Assimes T.L.
- Holm H.
- Preuss M.
- Stewart A.F.
- Barbalic M.
- Gieger C.
- Absher D.
- Aherrahrou Z.
- Allayee H.
- Altshuler D.
- Anand S.S.
- Andersen K.
- Anderson J.L.
- Ardissino D.
- Ball S.G.
- Balmforth A.J.
- Barnes T.A.
- Becker D.M.
- Becker L.C.
- Berger K.
- Bis J.C.
- Boekholdt S.M.
- Boerwinkle E.
- Braund P.S.
- Brown M.J.
- Burnett M.S.
- Buysschaert I.
- Carlquist J.F.
- Chen L.
- Cichon S.
- Codd V.
- Davies R.W.
- Dedoussis G.
- Dehghan A.
- Demissie S.
- Devaney J.M.
- Diemert P.
- Do R.
- Doering A.
- Eifert S.
- Mokhtari N.E.
- Ellis S.G.
- Elosua R.
- Engert J.C.
- Epstein S.E.
- de Faire U.
- Fischer M.
- Folsom A.R.
- Freyer J.
- Gigante B.
- Girelli D.
- Gretarsdottir S.
- Gudnason V.
- Gulcher J.R.
- Halperin E.
- Hammond N.
- Hazen S.L.
- Hofman A.
- Horne B.D.
- Illig T.
- Iribarren C.
- Jones G.T.
- Jukema J.W.
- Kaiser M.A.
- Kaplan L.M.
- Kastelein J.J.
- Khaw K.T.
- Knowles J.W.
- Kolovou G.
- Kong A.
- Laaksonen R.
- Lambrechts D.
- Leander K.
- Lettre G.
- Li M.
- Lieb W.
- Loley C.
- Lotery A.J.
- Mannucci P.M.
- Maouche S.
- Martinelli N.
- McKeown P.P.
- Meisinger C.
- Meitinger T.
- Melander O.
- Merlini P.A.
- Mooser V.
- Morgan T.
- Muhleisen T.W.
- Muhlestein J.B.
- Munzel T.
- Musunuru K.
- Nahrstaedt J.
- Nelson C.P.
- Nothen M.M.
- Olivieri O.
- Patel R.S.
- Patterson C.C.
- Peters A.
- Peyvandi F.
- Qu L.
- Quyyumi A.A.
- Rader D.J.
- Rallidis L.S.
- Rice C.
- Rosendaal F.R.
- Rubin D.
- Salomaa V.
- Sampietro M.L.
- Sandhu M.S.
- Schadt E.
- Schafer A.
- Schillert A.
- Schreiber S.
- Schrezenmeir J.
- Schwartz S.M.
- Siscovick D.S.
- Sivananthan M.
- Sivapalaratnam S.
- Smith A.
- Smith T.B.
- Snoep J.D.
- Soranzo N.
- Spertus J.A.
- Stark K.
- Stirrups K.
- Stoll M.
- Tang W.H.
- Tennstedt S.
- Thorgeirsson G.
- Thorleifsson G.
- Tomaszewski M.
- Uitterlinden A.G.
- van Rij A.M.
- Voight B.F.
- Wareham N.J.
- Wells G.A.
- Wichmann H.E.
- Wild P.S.
- Willenborg C.
- Witteman J.C.
- Wright B.J.
- Ye S.
- Zeller T.
- Ziegler A.
- Cambien F.
- Goodall A.H.
- Cupples L.A.
- Quertermous T.
- Marz W.
- Hengstenberg C.
- Blankenberg S.
- Ouwehand W.H.
- Hall A.S.
- Deloukas P.
- Thompson J.R.
- Stefansson K.
- Roberts R.
- Thorsteinsdottir U.
- O'Donnell C.J.
- McPherson R.
- Erdmann J.
- Samani N.J.
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease.
Nat Genet. 2011; 43: 333-338
View in Article
- Willer C.J.
- Schmidt E.M.
- Sengupta S.
- Peloso G.M.
- Gustafsson S.
- Kanoni S.
- Ganna A.
- Chen J.
- Buchkovich M.L.
- Mora S.
- Beckmann J.S.
- Bragg-Gresham J.L.
- Chang H.Y.
- Demirkan A.
- Den Hertog H.M.
- Do R.
- Donnelly L.A.
- Ehret G.B.
- Esko T.
- Feitosa M.F.
- Ferreira T.
- Fischer K.
- Fontanillas P.
- Fraser R.M.
- Freitag D.F.
- Gurdasani D.
- Heikkila K.
- Hypponen E.
- Isaacs A.
- Jackson A.U.
- Johansson A.
- Johnson T.
- Kaakinen M.
- Kettunen J.
- Kleber M.E.
- Li X.
- Luan J.
- Lyytikainen L.P.
- Magnusson P.K.
- Mangino M.
- Mihailov E.
- Montasser M.E.
- Muller-Nurasyid M.
- Nolte I.M.
- O'Connell J.R.
- Palmer C.D.
- Perola M.
- Petersen A.K.
- Sanna S.
- Saxena R.
- Service S.K.
- Shah S.
- Shungin D.
- Sidore C.
- Song C.
- Strawbridge R.J.
- Surakka I.
- Tanaka T.
- Teslovich T.M.
- Thorleifsson G.
- Van den Herik E.G.
- Voight B.F.
- Volcik K.A.
- Waite L.L.
- Wong A.
- Wu Y.
- Zhang W.
- Absher D.
- Asiki G.
- Barroso I.
- Been L.F.
- Bolton J.L.
- Bonnycastle L.L.
- Brambilla P.
- Burnett M.S.
- Cesana G.
- Dimitriou M.
- Doney A.S.
- Doring A.
- Elliott P.
- Epstein S.E.
- Eyjolfsson G.I.
- Gigante B.
- Goodarzi M.O.
- Grallert H.
- Gravito M.L.
- Groves C.J.
- Hallmans G.
- Hartikainen A.L.
- Hayward C.
- Hernandez D.
- Hicks A.A.
- Holm H.
- Hung Y.J.
- Illig T.
- Jones M.R.
- Kaleebu P.
- Kastelein J.J.
- Khaw K.T.
- Kim E.
- Klopp N.
- Komulainen P.
- Kumari M.
- Langenberg C.
- Lehtimaki T.
- Lin S.Y.
- Lindstrom J.
- Loos R.J.
- Mach F.
- McArdle W.L.
- Meisinger C.
- Mitchell B.D.
- Muller G.
- Nagaraja R.
- Narisu N.
- Nieminen T.V.
- Nsubuga R.N.
- Olafsson I.
- Ong K.K.
- Palotie A.
- Papamarkou T.
- Pomilla C.
- Pouta A.
- Rader D.J.
- Reilly M.P.
- Ridker P.M.
- Rivadeneira F.
- Rudan I.
- Ruokonen A.
- Samani N.
- Scharnagl H.
- Seeley J.
- Silander K.
- Stancakova A.
- Stirrups K.
- Swift A.J.
- Tiret L.
- Uitterlinden A.G.
- van Pelt L.J.
- Vedantam S.
- Wainwright N.
- Wijmenga C.
- Wild S.H.
- Willemsen G.
- Wilsgaard T.
- Wilson J.F.
- Young E.H.
- Zhao J.H.
- Adair L.S.
- Arveiler D.
- Assimes T.L.
- Bandinelli S.
- Bennett F.
- Bochud M.
- Boehm B.O.
- Boomsma D.I.
- Borecki I.B.
- Bornstein S.R.
- Bovet P.
- Burnier M.
- Campbell H.
- Chakravarti A.
- Chambers J.C.
- Chen Y.D.
- Collins F.S.
- Cooper R.S.
- Danesh J.
- Dedoussis G.
- de Faire U.
- Feranil A.B.
- Ferrieres J.
- Ferrucci L.
- Freimer N.B.
- Gieger C.
- Groop L.C.
- Gudnason V.
- Gyllensten U.
- Hamsten A.
- Harris T.B.
- Hingorani A.
- Hirschhorn J.N.
- Hofman A.
- Hovingh G.K.
- Hsiung C.A.
- Humphries S.E.
- Hunt S.C.
- Hveem K.
- Iribarren C.
- Jarvelin M.R.
- Jula A.
- Kahonen M.
- Kaprio J.
- Kesaniemi A.
- Kivimaki M.
- Kooner J.S.
- Koudstaal P.J.
- Krauss R.M.
- Kuh D.
- Kuusisto J.
- Kyvik K.O.
- Laakso M.
- Lakka T.A.
- Lind L.
- Lindgren C.M.
- Martin N.G.
- Marz W.
- McCarthy M.I.
- McKenzie C.A.
- Meneton P.
- Metspalu A.
- Moilanen L.
- Morris A.D.
- Munroe P.B.
- Njolstad I.
- Pedersen N.L.
- Power C.
- Pramstaller P.P.
- Price J.F.
- Psaty B.M.
- Quertermous T.
- Rauramaa R.
- Saleheen D.
- Salomaa V.
- Sanghera D.K.
- Saramies J.
- Schwarz P.E.
- Sheu W.H.
- Shuldiner A.R.
- Siegbahn A.
- Spector T.D.
- Stefansson K.
- Strachan D.P.
- Tayo B.O.
- Tremoli E.
- Tuomilehto J.
- Uusitupa M.
- van Duijn C.M.
- Vollenweider P.
- Wallentin L.
- Wareham N.J.
- Whitfield J.B.
- Wolffenbuttel B.H.
- Ordovas J.M.
- Boerwinkle E.
- Palmer C.N.
- Thorsteinsdottir U.
- Chasman D.I.
- Rotter J.I.
- Franks P.W.
- Ripatti S.
- Cupples L.A.
- Sandhu M.S.
- Rich S.S.
- Boehnke M.
- Deloukas P.
Discovery and refinement of loci associated with lipid levels.
Nat Genet. 2013; 45: 1274-1283
View in Article
- Do R.
- Willer C.J.
- Schmidt E.M.
- Sengupta S.
- Gao C.
- Peloso G.M.
- Gustafsson S.
- Kanoni S.
- Ganna A.
- Chen J.
- Buchkovich M.L.
- Mora S.
- Beckmann J.S.
- Bragg-Gresham J.L.
- Chang H.Y.
- Demirkan A.
- Den Hertog H.M.
- Donnelly L.A.
- Ehret G.B.
- Esko T.
- Feitosa M.F.
- Ferreira T.
- Fischer K.
- Fontanillas P.
- Fraser R.M.
- Freitag D.F.
- Gurdasani D.
- Heikkila K.
- Hypponen E.
- Isaacs A.
- Jackson A.U.
- Johansson A.
- Johnson T.
- Kaakinen M.
- Kettunen J.
- Kleber M.E.
- Li X.
- Luan J.
- Lyytikainen L.P.
- Magnusson P.K.
- Mangino M.
- Mihailov E.
- Montasser M.E.
- Muller-Nurasyid M.
- Nolte I.M.
- O'Connell J.R.
- Palmer C.D.
- Perola M.
- Petersen A.K.
- Sanna S.
- Saxena R.
- Service S.K.
- Shah S.
- Shungin D.
- Sidore C.
- Song C.
- Strawbridge R.J.
- Surakka I.
- Tanaka T.
- Teslovich T.M.
- Thorleifsson G.
- Van den Herik E.G.
- Voight B.F.
- Volcik K.A.
- Waite L.L.
- Wong A.
- Wu Y.
- Zhang W.
- Absher D.
- Asiki G.
- Barroso I.
- Been L.F.
- Bolton J.L.
- Bonnycastle L.L.
- Brambilla P.
- Burnett M.S.
- Cesana G.
- Dimitriou M.
- Doney A.S.
- Doring A.
- Elliott P.
- Epstein S.E.
- Eyjolfsson G.I.
- Gigante B.
- Goodarzi M.O.
- Grallert H.
- Gravito M.L.
- Groves C.J.
- Hallmans G.
- Hartikainen A.L.
- Hayward C.
- Hernandez D.
- Hicks A.A.
- Holm H.
- Hung Y.J.
- Illig T.
- Jones M.R.
- Kaleebu P.
- Kastelein J.J.
- Khaw K.T.
- Kim E.
- Klopp N.
- Komulainen P.
- Kumari M.
- Langenberg C.
- Lehtimaki T.
- Lin S.Y.
- Lindstrom J.
- Loos R.J.
- Mach F.
- McArdle W.L.
- Meisinger C.
- Mitchell B.D.
- Muller G.
- Nagaraja R.
- Narisu N.
- Nieminen T.V.
- Nsubuga R.N.
- Olafsson I.
- Ong K.K.
- Palotie A.
- Papamarkou T.
- Pomilla C.
- Pouta A.
- Rader D.J.
- Reilly M.P.
- Ridker P.M.
- Rivadeneira F.
- Rudan I.
- Ruokonen A.
- Samani N.
- Scharnagl H.
- Seeley J.
- Silander K.
- Stancakova A.
- Stirrups K.
- Swift A.J.
- Tiret L.
- Uitterlinden A.G.
- van Pelt L.J.
- Vedantam S.
- Wainwright N.
- Wijmenga C.
- Wild S.H.
- Willemsen G.
- Wilsgaard T.
- Wilson J.F.
- Young E.H.
- Zhao J.H.
- Adair L.S.
- Arveiler D.
- Assimes T.L.
- Bandinelli S.
- Bennett F.
- Bochud M.
- Boehm B.O.
- Boomsma D.I.
- Borecki I.B.
- Bornstein S.R.
- Bovet P.
- Burnier M.
- Campbell H.
- Chakravarti A.
- Chambers J.C.
- Chen Y.D.
- Collins F.S.
- Cooper R.S.
- Danesh J.
- Dedoussis G.
- de Faire U.
- Feranil A.B.
- Ferrieres J.
- Ferrucci L.
- Freimer N.B.
- Gieger C.
- Groop L.C.
- Gudnason V.
- Gyllensten U.
- Hamsten A.
- Harris T.B.
- Hingorani A.
- Hirschhorn J.N.
- Hofman A.
- Hovingh G.K.
- Hsiung C.A.
- Humphries S.E.
- Hunt S.C.
- Hveem K.
- Iribarren C.
- Jarvelin M.R.
- Jula A.
- Kahonen M.
- Kaprio J.
- Kesaniemi A.
- Kivimaki M.
- Kooner J.S.
- Koudstaal P.J.
- Krauss R.M.
- Kuh D.
- Kuusisto J.
- Kyvik K.O.
- Laakso M.
- Lakka T.A.
- Lind L.
- Lindgren C.M.
- Martin N.G.
- Marz W.
- McCarthy M.I.
- McKenzie C.A.
- Meneton P.
- Metspalu A.
- Moilanen L.
- Morris A.D.
- Munroe P.B.
- Njolstad I.
- Pedersen N.L.
- Power C.
- Pramstaller P.P.
- Price J.F.
- Psaty B.M.
- Quertermous T.
- Rauramaa R.
- Saleheen D.
- Salomaa V.
- Sanghera D.K.
- Saramies J.
- Schwarz P.E.
- Sheu W.H.
- Shuldiner A.R.
- Siegbahn A.
- Spector T.D.
- Stefansson K.
- Strachan D.P.
- Tayo B.O.
- Tremoli E.
- Tuomilehto J.
- Uusitupa M.
- van Duijn C.M.
- Vollenweider P.
- Wallentin L.
- Wareham N.J.
- Whitfield J.B.
- Wolffenbuttel B.H.
- Altshuler D.
- Ordovas J.M.
- Boerwinkle E.
- Palmer C.N.
- Thorsteinsdottir U.
- Chasman D.I.
- Rotter J.I.
- Franks P.W.
- Ripatti S.
- Cupples L.A.
- Sandhu M.S.
- Rich S.S.
Common variants associated with plasma triglycerides and risk for coronary artery disease.
Nat Genet. 2013; 45: 1345-1352
View in Article
- Jorgensen A.B.
- Frikke-Schmidt R.
- West A.S.
- Grande P.
- Nordestgaard B.G.
- Tybjaerg-Hansen A.
Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction.
Eur Heart J. 2013; 34: 1826-1833
View in Article
- Varbo A.
- Benn M.
- Tybjaerg-Hansen A.
- Jorgensen A.B.
- Frikke-Schmidt R.
- Nordestgaard B.G.
Remnant cholesterol as a causal risk factor for ischemic heart disease.
J Am Coll Cardiol. 2013; 61: 427-436
View in Article
- Varbo A.
- Benn M.
- Tybjaerg-Hansen A.
- Nordestgaard B.G.
Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation.
Circulation. 2013; 128: 1298-1309
View in Article
- Thomsen M.
- Varbo A.
- Tybjaerg-Hansen A.
- Nordestgaard B.G.
Low nonfasting triglycerides and reduced all-cause mortality: a Mendelian randomization study.
Clin Chem. 2014; 60: 737-746
View in Article
- Holmes M.V.
- Asselbergs F.W.
- Palmer T.M.
- Drenos F.
- Lanktree M.B.
- Nelson C.P.
- Dale C.E.
- Padmanabhan S.
- Finan C.
- Swerdlow D.I.
- Tragante V.
- van Iperen E.P.
- Sivapalaratnam S.
- Shah S.
- Elbers C.C.
- Shah T.
- Engmann J.
- Giambartolomei C.
- White J.
- Zabaneh D.
- Sofat R.
- McLachlan S.
- Doevendans P.A.
- Balmforth A.J.
- Hall A.S.
- North K.E.
- Almoguera B.
- Hoogeveen R.C.
- Cushman M.
- Fornage M.
- Patel S.R.
- Redline S.
- Siscovick D.S.
- Tsai M.Y.
- Karczewski K.J.
- Hofker M.H.
- Verschuren W.M.
- Bots M.L.
- van der Schouw Y.T.
- Melander O.
- Dominiczak A.F.
- Morris R.
- Ben-Shlomo Y.
- Price J.
- Kumari M.
- Baumert J.
- Peters A.
- Thorand B.
- Koenig W.
- Gaunt T.R.
- Humphries S.E.
- Clarke R.
- Watkins H.
- Farrall M.
- Wilson J.G.
- Rich S.S.
- de Bakker P.I.
- Lange L.A.
- Davey S.G.
- Reiner A.P.
- Talmud P.J.
- Kivimaki M.
- Lawlor D.A.
- Dudbridge F.
- Samani N.J.
- Keating B.J.
- Hingorani A.D.
- Casas J.P.
Mendelian randomization of blood lipids for coronary heart disease.
Eur Heart J. 2015; 36: 539-550
View in Article
- Wittrup H.H.
- Tybjaerg-Hansen A.
- Nordestgaard B.G.
Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis.
Circulation. 1999; 99: 2901-2907
View in Article
- Breckenridge W.C.
- Little J.A.
- Steiner G.
- Chow A.
- Poapst M.
Hypertriglyceridemia associated with deficiency of apolipoprotein C-II.
N Engl J Med. 1978; 298: 1265-1273
View in Article
- Reina M.
- Brunzell J.D.
- Deeb S.S.
Molecular basis of familial chylomicronemia: mutations in the lipoprotein lipase and apolipoprotein C-II genes.
J Lipid Res. 1992; 33: 1823-1832
View in Article
- PubMed
- Google Scholar
- Irvin M.R.
- Zhi D.
- Joehanes R.
- Mendelson M.
- Aslibekyan S.
- Claas S.A.
- Thibeault K.S.
- Patel N.
- Day K.
- Jones L.W.
- Liang L.
- Chen B.H.
- Yao C.
- Tiwari H.K.
- Ordovas J.M.
- Levy D.
- Absher D.
- Arnett D.K.
Epigenome-wide association study of fasting blood lipids in the Genetics of Lipid-lowering Drugs and Diet Network study.
Circulation. 2014; 130: 565-572
View in Article
- Taylor A.E.
- Davies N.M.
- Ware J.J.
- VanderWeele T.
- Smith G.D.
- Munafo M.R.
Mendelian randomization in health research: using appropriate genetic variants and avoiding biased estimates.
Econ Hum Biol. 2014; 13: 99-106
View in Article
- Voight B.F.
- Peloso G.M.
- Orho-Melander M.
- Frikke-Schmidt R.
- Barbalic M.
- Jensen M.K.
- Hindy G.
- Holm H.
- Ding E.L.
- Johnson T.
- Schunkert H.
- Samani N.J.
- Clarke R.
- Hopewell J.C.
- Thompson J.F.
- Li M.
- Thorleifsson G.
- Newton-Cheh C.
- Musunuru K.
- Pirruccello J.P.
- Saleheen D.
- Chen L.
- Stewart A.
- Schillert A.
- Thorsteinsdottir U.
- Thorgeirsson G.
- Anand S.
- Engert J.C.
- Morgan T.
- Spertus J.
- Stoll M.
- Berger K.
- Martinelli N.
- Girelli D.
- McKeown P.P.
- Patterson C.C.
- Epstein S.E.
- Devaney J.
- Burnett M.S.
- Mooser V.
- Ripatti S.
- Surakka I.
- Nieminen M.S.
- Sinisalo J.
- Lokki M.L.
- Perola M.
- Havulinna A.
- de Faire U.
- Gigante B.
- Ingelsson E.
- Zeller T.
- Wild P.
- de Bakker P.I.
- Klungel O.H.
- Maitland-van der Zee A.H.
- Peters B.J.
- de B.A.
- Grobbee D.E.
- Kamphuisen P.W.
- Deneer V.H.
- Elbers C.C.
- Onland-Moret N.C.
- Hofker M.H.
- Wijmenga C.
- Verschuren W.M.
- Boer J.M.
- van der Schouw Y.T.
- Rasheed A.
- Frossard P.
- Demissie S.
- Willer C.
- Do R.
- Ordovas J.M.
- Abecasis G.R.
- Boehnke M.
- Mohlke K.L.
- Daly M.J.
- Guiducci C.
- Burtt N.P.
- Surti A.
- Gonzalez E.
- Purcell S.
- Gabriel S.
- Marrugat J.
- Peden J.
- Erdmann J.
- Diemert P.
- Willenborg C.
- Konig I.R.
- Fischer M.
- Hengstenberg C.
- Ziegler A.
- Buysschaert I.
- Lambrechts D.
- Van de Werf F.
- Fox K.A.
- El Mokhtari N.E.
- Rubin D.
- Schrezenmeir J.
- Schreiber S.
- Schafer A.
- Danesh J.
- Blankenberg S.
- Roberts R.
- McPherson R.
- Watkins H.
- Hall A.S.
- Overvad K.
- Rimm E.
- Boerwinkle E.
- Tybjaerg-Hansen A.
- Cupples L.A.
- Reilly M.P.
- Melander O.
- Mannucci P.M.
- Ardissino D.
- Siscovick D.
- Elosua R.
- Stefansson K.
- O'Donnell C.J.
- Salomaa V.
- Rader D.J.
- Peltonen L.
- Schwartz S.M.
- Altshuler D.
- Kathiresan S.
Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study.
Lancet. 2012; 380: 572-580
View in Article
- Frikke-Schmidt R.
- Nordestgaard B.G.
- Stene M.C.
- Sethi A.A.
- Remaley A.T.
- Schnohr P.
- Grande P.
- Tybjaerg-Hansen A.
Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease.
JAMA. 2008; 299: 2524-2532
View in Article
- Johannsen T.H.
- Kamstrup P.R.
- Andersen R.V.
- Jensen G.B.
- Sillesen H.
- Tybjaerg-Hansen A.
- Nordestgaard B.G.
Hepatic lipase, genetically elevated high-density lipoprotein, and risk of ischemic cardiovascular disease.
J Clin Endocrinol Metab. 2009; 94: 1264-1273
View in Article
- Barter P.J.
- Caulfield M.
- Eriksson M.
- Grundy S.M.
- Kastelein J.J.
- Komajda M.
- Lopez-Sendon J.
- Mosca L.
- Tardif J.C.
- Waters D.D.
- Shear C.L.
- Revkin J.H.
- Buhr K.A.
- Fisher M.R.
- Tall A.R.
- Brewer B.
Effects of torcetrapib in patients at high risk for coronary events.
N Engl J Med. 2007; 357: 2109-2122
View in Article
- Schwartz G.G.
- Olsson A.G.
- Abt M.
- Ballantyne C.M.
- Barter P.J.
- Brumm J.
- Chaitman B.R.
- Holme I.M.
- Kallend D.
- Leiter L.A.
- Leitersdorf E.
- McMurray J.J.
- Mundl H.
- Nicholls S.J.
- Shah P.K.
- Tardif J.C.
- Wright R.S.
Effects of dalcetrapib in patients with a recent acute coronary syndrome.
N Engl J Med. 2012; 367: 2089-2099
View in Article
- Hilleman D.
- Smer A.
Prescription omega-3 fatty acid products and dietary supplements are not interchangeable.
Manag Care. 2016; 25: 46-52
View in Article
- PubMed
- Google Scholar
Vascepa [package Insert]. Amarin Pharma Inc, Bedminster, NJ2015
View in Article
- Google Scholar
- Harris W.S.
- Ginsberg H.N.
- Arunakul N.
- Shachter N.S.
- Windsor S.L.
- Adams M.
- Berglund L.
- Osmundsen K.
Safety and efficacy of Omacor in severe hypertriglyceridemia.
J Cardiovasc Risk. 1997; 4: 385-391
View in Article
- Pownall H.J.
- Brauchi D.
- Kilinc C.
- Osmundsen K.
- Pao Q.
- Payton-Ross C.
- Gotto Jr., A.M.
- Ballantyne C.M.
Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins.
Atherosclerosis. 1999; 143: 285-297
View in Article
- Davidson M.H.
- Stein E.A.
- Bays H.E.
- Maki K.C.
- Doyle R.T.
- Shalwitz R.A.
- Ballantyne C.M.
- Ginsberg H.N.
Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.
Clin Ther. 2007; 29: 1354-1367
View in Article
- Bays H.E.
- Ballantyne C.M.
- Kastelein J.J.
- Isaacsohn J.L.
- Braeckman R.A.
- Soni P.N.
Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial).
Am J Cardiol. 2011; 108: 682-690
View in Article
- Ballantyne C.M.
- Bays H.E.
- Kastelein J.J.
- Stein E.
- Isaacsohn J.L.
- Braeckman R.A.
- Soni P.N.
Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).
Am J Cardiol. 2012; 110: 984-992
View in Article
- Kastelein J.J.P.
- Maki K.C.
- Susekov A.
- Ezhov M.
- Nordestgaard B.G.
- Machielse B.N.
- Kling D.
- Davidson M.H.
Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial.
J Clin Lipidol. 2014; 8: 94-108
View in Article
- Maki K.C.
- Orloff D.G.
- Nicholls S.J.
- Dunbar R.L.
- Roth E.M.
- Curcio D.
- Johnson J.
- Kling D.
- Davidson M.H.
A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial).
Clin Ther. 2013; 35: 1400-1411
View in Article
Lovaza [package Insert]. GlaxoSmithKline, Research Triangle Park, NC2014
View in Article
- Google Scholar
Epanova [package Insert]. AstraZeneca Pharmaceuticals LP, Wilmington, DE2014
View in Article
- Google Scholar
Omtryg [package Insert]. Trygg Pharma, Inc., Arlington, VA2014
View in Article
- Google Scholar
- Ballantyne C.M.
- Bays H.E.
- Braeckman R.A.
- Philip S.
- Stirtan W.G.
- Doyle Jr., R.T.
- Soni P.N.
- Juliano R.A.
Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies.
Circulation. 2014; 130 ([abstract]): A16803
View in Article
- Google Scholar
- Ito M.K.
Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature.
Atherosclerosis. 2015; 242: 647-656
View in Article
- Davidson M.H.
- Rosenson R.S.
- Maki K.C.
- Nicholls S.J.
- Ballantyne C.M.
- Mazzone T.
- Carlson D.M.
- Williams L.A.
- Kelly M.T.
- Camp H.S.
- Lele A.
- Stolzenbach J.C.
Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST).
Arterioscler Thromb Vasc Biol. 2014; 34: 1298-1306
View in Article
- Mozaffarian D.
- Wu J.H.
Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events.
J Am Coll Cardiol. 2011; 58: 2047-2067
View in Article
Manku MS, Best practices: why EPA only? Understanding the distinctions between high-dose prescription EPA-only drug intervention for treating disease versus omega-3 dietary supplementation for promotion of health. Intern Med News. December 2015. Supplement.
View in Article
- Google Scholar
- Borow K.M.
- Nelson J.R.
- Mason R.P.
Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis.
Atherosclerosis. 2015; 242: 357-366
View in Article
- Cannon C.P.
- Blazing M.A.
- Giugliano R.P.
- McCagg A.
- White J.A.
- Theroux P.
- Darius H.
- Lewis B.S.
- Ophuis T.O.
- Jukema J.W.
- De Ferrari G.M.
- Ruzyllo W.
- De L.P.
- Im K.
- Bohula E.A.
- Reist C.
- Wiviott S.D.
- Tershakovec A.M.
- Musliner T.A.
- Braunwald E.
- Califf R.M.
Ezetimibe added to statin therapy after acute coronary syndromes.
N Engl J Med. 2015; 372: 2387-2397
View in Article
- Blom D.J.
- Hala T.
- Bolognese M.
- Lillestol M.J.
- Toth P.D.
- Burgess L.
- Ceska R.
- Roth E.
- Koren M.J.
- Ballantyne C.M.
- Monsalvo M.L.
- Tsirtsonis K.
- Kim J.B.
- Scott R.
- Wasserman S.M.
- Stein E.A.
A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.
N Engl J Med. 2014; 370: 1809-1819
View in Article
- Robinson J.G.
- Farnier M.
- Krempf M.
- Bergeron J.
- Luc G.
- Averna M.
- Stroes E.S.
- Langslet G.
- Raal F.J.
- Shahawy M.E.
- Koren M.J.
- Lepor N.E.
- Lorenzato C.
- Pordy R.
- Chaudhari U.
- Kastelein J.J.
Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.
N Engl J Med. 2015; 372: 1489-1499
View in Article
- Sabatine M.S.
- Giugliano R.P.
- Wiviott S.D.
- Raal F.J.
- Blom D.J.
- Robinson J.
- Ballantyne C.M.
- Somaratne R.
- Legg J.
- Wasserman S.M.
- Scott R.
- Koren M.J.
- Stein E.A.
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.
N Engl J Med. 2015; 372: 1500-1509
View in Article

Article Info

Publication History

Published online: April 19, 2016

Accepted: April 6, 2016

Received in revised form: April 6, 2016

Received: December 5, 2015

Footnotes

See page 142 for disclosure information.

Identification

DOI: https://doi.org/10.1016/j.amjcard.2016.04.004

Copyright

User License

Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0) |

How you can reuse Information Icon

ScienceDirect

Access this article on ScienceDirect

Toggle Thumbstrip

Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Triglycerides and Triglyceride-Rich Lipoproteins in the Causal Pathway of Cardiovascular Disease

Overview of TRL Metabolism

Genetic Evidence for Triglycerides and TRLs in the Causal Pathway of ASCVD

Mutational analyses/exome sequencing

Genome-wide association studies

Mendelian randomization studies

Clinical implications

Acknowledgment

Disclosures

References

Article Info

Publication History

Footnotes

Identification

Copyright

User License

Permitted

For non-commercial purposes:

Not Permitted

ScienceDirect

Related Articles